

Specter

10/539,151

02/21/2007

L3 ANSWER 69 OF 69 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1955:78071 CAPLUS

DOCUMENT NUMBER: 49:78071

ORIGINAL REFERENCE NO.: 49:14810g-i,14811a

TITLE: (5-Benzyloxy-3-indolyl)alkanamides

INVENTOR(S): Speeter, Merrill E.

PATENT ASSIGNEE(S): Upjohn Co. DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2692882		19541026	US 1952-279931	19520401

GI For diagram(s), see printed CA Issue.

AB I (X is Ph, halophenyl, lower alkoxyphenyl, or lower alkylphenyl; Y is H, Ph, halophenyl, lower alkoxyphenyl, or lower alkylphenyl; R' and R'' are H or lower alkyl; n is 0 or 1; and Z is a secondary amine radical) are prepared by the following exemplary procedure. A Grignard reagent prepared from 4.25 g. MeI and 2.4 g. Mg in 200 ml. Et20 added to 5.5 g. 5-benzyloxyindole in 200 ml. Et20, the solution refluxed 30 min., cooled in an ice-bath, 5.9 g. ClCH2CONMeCH2Ph in 200 ml. Et20 added, the mixture stirred, the Et20 distilled off, the residue warmed 3 hrs. on a steam bath, cooled, about 500 ml. Et20 added, then, with vigorous stirring, 5 ml. AcOH and 95 ml. H2O, the mixture allowed to stand overnight, and the product filtered and recrystd. gives 7.5 g. 2-(5-benzyloxy-3-indolyl)-N-benzyl-N-methylacetamide, m. 151-2° (from iso-PrOH). Similarly prepared: in 69% yield, the N,N-di-PhCH2 analog, m. 156-7°; and in 30% yield, 2-(5-benzyloxy-3-indolyl)benzylacetamide, m. 185-6°.

TT 725227-53-2P, 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-methyl-857776-54-6P, 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-isopropyl-857776-60-4P, 3-Indoleacetamide, N,N-dibenzyl-5-(benzyloxy)-872786-56-6P, Indole, 5-(benzyloxy)-3-(piperidinocarbonylmethyl)-

RL: PREP (Preparation)
 (preparation of)

RN 725227-53-2 CAPLUS

CN 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-methyl- (5CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & \\ \hline N & \\ O & Me \\ \hline \parallel & \\ CH_2-C-N-CH_2-Ph \end{array}$$

RN 857776-54-6 CAPLUS

CN 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-isopropyl- (5CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & \\ \text{Ph-CH}_2-\text{O} & & \\ & & \\ \text{CH}_2-\text{C-N-Pr-i} \end{array}$$

RN 857776-60-4 CAPLUS

CN 3-Indoleacetamide, N, N-dibenzyl-5-(benzyloxy)- (5CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & \\ \text{Ph-CH}_2-\text{O} & & \\ & & \\ \text{CH}_2-\text{C-N-CH}_2-\text{Ph} \\ \end{array}$$

RN 872786-56-6 CAPLUS

CN Piperidine, 1-[[5-(benzyloxy)-3-indolyl]acetyl]- (5CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O \\ \hline \\ Ph-CH_2-O \end{array}$$

Connecting via Winsock to STN

Claims 33-35

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
                Web Page URLs for STN Seminar Schedule - N. America
NEWS 1
                "Ask CAS" for self-help around the clock
NEWS 2
                The Derwent World Patents Index suite of databases on STN
     3 OCT 23
NEWS
                has been enhanced and reloaded
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 6 NOV 10 CA/CAplus F-Term thesaurus enhanced
                STN Express with Discover! free maintenance release Version
        NOV 10
NEWS
                8.01c now available
        NOV 20 CA/CAplus to MARPAT accession number crossover limit increased
NEWS 8
                to 50,000
        DEC 01 CAS'REGISTRY updated with new ambiguity codes
NEWS 9
NEWS 10 DEC 11 CAS REGISTRY chemical nomenclature enhanced
        DEC 14 WPIDS/WPINDEX/WPIX manual codes updated
NEWS 11
                GBFULL and FRFULL enhanced with IPC 8 features and
        DEC 14
NEWS 12
                functionality
        DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced
NEWS 13
                with preparation role
                CA/CAplus patent kind codes updated
         DEC 18
NEWS 14
                MARPAT to CA/CAplus accession number crossover limit increased
NEWS 15 DEC 18
                to 50,000
                MEDLINE updated in preparation for 2007 reload
        DEC 18
NEWS 16
                CA/CAplus enhanced with more pre-1907 records
        DEC 27
NEWS 17
         JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 18
NEWS 19
        JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded
        JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 20
NEWS 21
                WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
         JAN 16
NEWS 22
                CA/CAplus updated with revised CAS roles
         JAN 22
        JAN 22 CA/CAplus enhanced with patent applications from India
NEWS 23
        JAN 29 PHAR reloaded with new search and display fields
NEWS 24
        JAN 29 CAS Registry Number crossover limit increased to 300,000 in
NEWS 25
                multiple databases
        FEB 13 CASREACT coverage to be extended
NEWS 26
NEWS 27 Feb 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 28
        Feb 15 RUSSIAPAT enhanced with pre-1994 records
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
             MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
             AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS
             STN Operating Hours Plus Help Desk Availability
NEWS LOGIN
             Welcome Banner and News Items
              For general information regarding STN implementation of IPC 8
NEWS IPC8
             X.25 communication option no longer available
NEWS X25
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:12:58 ON 21 FEB 2007

=> fil casreact
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'CASREACT' ENTERED AT 16:13:04 ON 21 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT: 1840 - 18 Feb 2007 VOL 146 ISS 8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> Uploading C:\Program Files\Stnexp\Queries\10539151\claim 33.str

10/539,151 02/21/2007

chain nodes :

10 11 12 16 27 28 29 35 36

ring nodes :

1 2 3 4 5 6 7 8 9 18 19 20 21 22 23 24 25 26

ring/chain nodes :

13 14 15 30 31 32

chain bonds :

7-11 8-10 11-12 12-13 24-28 25-27 28-29 29-30 35-36

ring/chain bonds :

13-14 13-15 30-31 30-32

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 18-19 18-23 19-20 20-21 21-22

22-23 22-24 23-26 24-25 25-26

exact/norm bonds :

5-7 6-9 7-8 8-9 13-14 13-15 22-24 23-26 24-25 25-26 30-31 30-32

exact bonds :

7-11 8-10 11-12 12-13 24-28 25-27 28-29 29-30 35-36

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 18-19 18-23 19-20 20-21 21-22 22-23

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 35:CLASS 36:CLASS 37:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1

STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT * Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 16:13:25 FILE 'CASREACT'

SCREENING COMPLETE - 102186 REACTIONS TO VERIFY FROM 5702 DOCUMENTS


100.0% DONE 102186 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.05

L2 0 SEA SSS FUL L1 (0 REACTIONS)

=>

Uploading C:\Program Files\Stnexp\Queries\10539151\claim 34.str



chain nodes : 10 11 12 16 27 28 29 35 37 ring nodes : 1 2 3 4 5 6 7 8 9 18 19 20 21 22 23 24 25 26 ring/chain nodes: 13 14 15 30 31 32 chain bonds : 7-11 8-10 11-12 12-13 24-28 25-27 28-29 29-30 35-37 ring/chain bonds : 13-14 13-15 30-31 30-32 ring bonds : 4-5 5-6 5-7 6-9 7-8 8-9 18-19 18-23 19-20 20-21 21-22 1-2 1-6 2-3 3-4 23-26 24-25 25-26 22-23 22-24 exact/norm bonds : 5-7 6-9 7-8 8-9 13-14 13-15 22-24 23-26 24-25 25-26 30-31 30-32 exact bonds : 7-11 8-10 11-12 12-13 24-28 25-27 28-29 29-30 35-37 normalized bonds : 1-2 1-6 2-3 3-4 4-5 5-6 18-19 18-23 19-20 20-21 21-22 22-23

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 35:CLASS 36:Atom 37:CLASS

L3 STRUCTURE UPLOADED

=> d L3 HAS NO ANSWERS L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.

=> s 13 full
FULL SEARCH INITIATED 16:14:39 FILE 'CASREACT'
SCREENING COMPLETE - 21936 REACTIONS TO VERIFY FROM 1426 DOCUMENTS

100.0% DONE 21936 VERIFIED 0 HIT RXNS 0 DOCS


SEARCH TIME: 00.00.01

L4

O SEA SSS FUL L3 (O REACTIONS)

=>

Uploading C:\Program Files\Stnexp\Queries\10539151\claim 35.str



chain nodes :

10 11 12 16 27 28 29 33

ring nodes :

1 2 3 4 5 6 7 8 9 18 19 20 21 22 23 24 25 26

ring/chain nodes:

13 14 15 30 31 32

chain bonds :

7-11 8-10 11-12 12-13 24-28 25-27 28-29 29-30

ring/chain bonds :

13-14 13-15 30-31 30-32

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 18-19 18-23 19-20 20-21 21-22

22-23 22-24 23-26 24-25 25-26

exact/norm bonds :

5-7 6-9 7-8 8-9 13-14 13-15 22-24 23-26 24-25 25-26 30-31 30-32

exact bonds :

7-11 8-10 11-12 12-13 24-28 25-27 28-29 29-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 18-19 18-23 19-20 20-21 21-22 22-23

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:Atom fragments assigned product role:

containing 18

fragments assigned reactant/reagent role:

containing 1

STRUCTURE UPLOADED L5

=> d

L5 HAS NO ANSWERS

L5

STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

10/539,151

02/21/2007

=> s 15 full

FULL SEARCH INITIATED 16:18:19 FILE 'CASREACT'

SCREENING COMPLETE - 168 REACTIONS TO VERIFY FROM 22 DOCUMENTS

100.0% DONE 168 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L5 (0 REACTIONS)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

343.80 344.01

STN INTERNATIONAL LOGOFF AT 16:18:48 ON 21 FEB 2007

Connecting via Winsock to STN

Claim 36

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * *
NEWS	1			Web Page URLs for STN Seminar Schedule - N. America
	2			"Ask CAS" for self-help around the clock
NEWS			23	The Derwent World Patents Index suite of databases on STN
	-		· -	has been enhanced and reloaded
NEWS	4	OCT	30	CHEMLIST enhanced with new search and display field
NEWS				JAPIO enhanced with IPC 8 features and functionality
NEWS				CA/CAplus F-Term thesaurus enhanced
NEWS	7	NOV	10	STN Express with Discover! free maintenance release Version
				8.01c now available
NEWS	8	NOV	20	CA/CAplus to MARPAT accession number crossover limit increased
				to 50,000
NEWS	9	DEC	01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC	11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC	14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC	14	GBFULL and FRFULL enhanced with IPC 8 features and
				functionality
NEWS	13	DEC	18	CA/CAplus pre-1967 chemical substance index entries enhanced
				with preparation role
NEWS	14	DEC	18	CA/CAplus patent kind codes updated
NEWS	15	DEC	18	MARPAT to CA/CAplus accession number crossover limit increased
				to 50,000
NEWS	16	DEC	18	MEDLINE updated in preparation for 2007 reload
NEWS	17			CA/CAplus enhanced with more pre-1907 records
NEWS	18	JAN	08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN	16	
NEWS	20			IPC version 2007.01 thesaurus available on STN
NEWS				WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS				CA/CAplus updated with revised CAS roles
NEWS				CA/CAplus enhanced with patent applications from India
NEWS				♣ ↓
NEWS	25	JAN	29	CAS Registry Number crossover limit increased to 300,000 in
),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			10	multiple databases
				CASREACT coverage to be extended
				PATDPASPC enhanced with Drug Approval numbers
NEWS	28	reb	15	RUSSIAPAT enhanced with pre-1994 records
NEWS	FYDI	RESS	NOI	VEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MEMO	Ť, V, T, T	טטטא.		CINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
				D CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
			MIN	CONNENT DIOCOVER TIEB TO DITIED 25 DELIBRIDER 2000.
NEWS	HOU	RS	STI	N Operating Hours Plus Help Desk Availability
NEWS				lcome Banner and News Items
NEWS			_	r general information regarding STN implementation of IPC 8
NEWS				25 communication option no longer available
				The state of the s

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:36:24 ON 21 FEB 2007

=> fil reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

COST IN U.S. DOLLARS

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:36:28 ON 21 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6 DICTIONARY FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

Uploading C:\Program Files\Stnexp\Queries\10539151\claim 36 XIIIa.str

chain nodes :

=>


10 11 12 16 ring nodes : 1 2 3 4 5 6 7 8 9 ring/chain nodes: 13 14 15 chain bonds : 7-11 8-10 11-12 12-13 13-16 ring/chain bonds : 13-14 13-15 ring bonds : 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 exact/norm bonds : 5-7 6-9 7-8 8-9 13-14 13-15 exact bonds : 7-11 8-10 11-12 12-13 13-16 normalized bonds: 1-2 1-6 2-3 3-4 4-5 5-6

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d L1 HAS NO ANSWERS L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 16:36:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 164 TO ITERATE

100.0% PROCESSED 164 ITERATIONS 8 ANSWERS

SEARCH TIME: 00.00.01

L2 8 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 172.10 172.31

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 16:36:47 ON 21 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Feb 2007 VOL 146 ISS 9 FILE LAST UPDATED: 19 Feb 2007 (20070219/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 12 L3 7 L2

=> d ibib abs hitstr 1-7

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN 1997:465610 CAPLUS

ACCESSION NUMBER: DOCUMENT NUMBER: 127:176360

4-ethyloctahydroindolo[2,3-a]quinolizine-

Synthesis of

2-carbaldehydes

AUTHOR (S):

Bonjoch, Josep; Fernandez, Joan-Carles; Terricabras, Dolors; Valls, Nativitat

Lab. Org. Chemistry, Fac. Pharmacy, Univ. Barcelona, CORPORATE SOURCE:

Barcelona, 08028, Spain Tetrahedron (1997), 53(27), 9407-9414

SOURCE: CODEN: TETRAB: ISSN: 0040-4020

PUBLISHER: DOCUMENT TYPE: Elsevier Journal

LANGUAGE:

English CASREACT 127:176360

OTHER SOURCE(S):

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

The isomerization-cyclization of tetrahydropyridine I by AcOH leads to 4-ethyloctahydroindolo{2,3-a}quinolizine-2-carbaldehydes II. When the process is carried out with aqueous AcOH, indolizidinoindole III is formed as

a byproduct in a competitive way. Compound I is available via reductive cyanation of pyridinium salt IV followed by treatment of nitrile V with ethylmagnesium bromide.

194086-75-4P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of ethylindoloquinolizinecarbaldehydes)

194086-75-4 CAPLUS

Boron, [3-[2-[4-(dimethoxymethyl)-3,6-dihydro-1(2H)-pyridinylkN]ethyl]-lH-indole]trihydro-, (T-4)- (9CI) (CA INDEX NAME)

REFERENCE COUNT: THIS

THERE ARE 27 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

The title compds. I [R1 = CH2CH2NR7R8, Q1, Q2 (dotted line represents an optional double bond), etc.; R7,R8 = H, C1-6alkyl, aryl, C1-3alkylaryl, etc.; X = 0, NH, S; Z = (un) substituted 5- or 6-membered heterocycleo; R7R8 may form a 4- to 6-membered ring], which are potent serotonin

(5-HT1) receptor antagonists (no data), useful in the treatment of hypertension (no data), depression (no data), anxiety (no data), eating disorders (no data), obesity (no data), etc., are prepared Thus, (R)-5-amino-3-(pyrrolidin-2-ylmethyl)-1-H-indole was prepared by hydrogenolysis of (R)-3-(N-benzyloxycarbonylpyrrolidin-2-ylmethyl)-5-dibenzylamino-1Hindole.

IT 147659-18-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reaction of, in preparation of indole derivative

serotonin receptor antagonists)

147659-18-5 CAPLUS Boron, (N, N-dimethyl-5-nitro-1H-indole-3-ethanamine-Na) trihydro-,

(T-4) - (9CI) (CA INDEX NAME)

ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

1993:649833 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 119:249833

TITLE: Indole derivatives which are potent serotinin receptor

antagonists INVENTOR(S): Macor, John E. Pfizer Inc., USA PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 65 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PAT	TENT NO.			KINE		DATE		AP:	PLICAT	ION NO). 		DATE
WO	9311106								1992-	VS8306			19921006
	W: AU,												
	RW: AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB, G	R, IE,	IT, I	JU, M	C, N	L, SE
AU	9228961			A		1993	0628	UA	1992-	28961			19921006
AU	671959			B2		1996	0919						19921006
EP	619805			A1		1994	1019	EP	1992-	922831	Ļ		19921006
EP	619805			Bl		2000	0315						
	R: AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB, G	R, IE,	IT, I	LI, L	U, N	L, SE
JP	06510793	3		T		1994	1201	JP	1992-	510086	3		19921006
JP	2840448			B2		1998	1224						19921006 19921006 19921006
HU	69705			A2		1995	0928	HU	1994-	1398			19921006
BR	9206810			A		1995	1031	BR	1992-	6810			19921006
LZ	7010/4			50		1221	V3IZ	L	エフフリマ	1700			12271000
PL	173875			B1		1998	0529	PL	1992-	303794			19921006
RU	2126399			C1		1999	0220	RU	1994-	28107			19921006 19921006 19921006
AT	190608			T		2000	0415	AT	1992-	922831	L		19921006
ES	2143992			T3		2000	0601	ES	1992-	922831	L		19921006
CA	2124206			С		2001	0227	CA	1992-	212420	06		19921006
IL	103798			A		2000							19921119
EG	21209			A		2001	0131	EG					19921123
CN	1072679			A		1993	0602	CN					19921124
CN	1045294			R		1999	0929						
ZA	9209082			A		1994	0524	ZΑ	1992-	9082			19921124
US	5639752			A		1997	0617	VS	1994~	244043	3		19940520
FI	9402395			A		1994	0524	FI	1994-	2395			19921124 19940520 19940524
NO	9401918			A		1994	0524	NO	1994-	1918			19940524 19940524
MO	201225			201		1007	0000						
JP	08239363	3		A		1996	0917	JP	1996-	38320			19960226
GR	3033370			TЗ		2000	0929	GR	2000-	401055	5		19960226 20000505
	APPLN.							US	1991-	796744	1	A2	19911125
								WO	1992-	·us8306	5	А	19921006

OTHER SOURCE(S):

MARPAT 119:249833

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN 1993:233812 CAPLUS

ACCESSION NUMBER:

DOCUMENT NUMBER: 118:233812

TITLE: A simple synthesis of 5-amino-3-(2-

dimethylaminoethyl)indole [5-amino-N,Ndimethyltryptamine)

AUTHOR (S): Macor, John E.; Post, Ronald; Ryan, Kevin Cent. Res. Div., Pfizer Inc., Groton, CT, 06355, USA CORPORATE SOURCE:

Synthetic Communications (1993), 23(1), 65-72

SOURCE: CODEN: SYNCAV; ISSN: 0039-7911

DOCUMENT TYPE: Journal LANGUAGE: English

CASREACT 118:233812 OTHER SOURCE(S):

A short (three step) synthesis of the title compound (I, R = NH2) from com.

available starting materials is presented. Reaction of 5-nitroindole with

oxalyl chloride followed by dimethylamine afforded N, N-di-methyl-5nitroindole-3-glyoxamide (II), which was reduced by diborane to 5-nitro-3-(2-dimethylaminoethyl)indole (I, R = NO2). Catalytic reduction of I

(R = NO2) afforded the title compound in 19% overall yield from

5-nitroindole. 147659-18-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant 'or reagent)

(preparation and decomplexation ot) 147659-18-5 CAPLUS

Boron, (N,N-dimethyl-5-nitro-1H-indole-3-ethanamine-Na)trihydro-, (T-4)-(9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN 1992:174023 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

116:174023 TITLE:

The synthesis of pyrano[3,2-e]indoles and pyrano[2,3-f]indoles as rotationally restricted phenolic analogs of the neurotransmitter serotonin Macro, John E.; Ryan, Kevin; Newman, Michael E.

Cent. Res. Div., Pfizer Inc., Groton, CT, 06340, USA CORPORATE SOURCE: Tetrahedron (1992), 48(6), 1039-52 SOURCE:

CODEN: TETRAB; ISSN: 0040-4020 Journal

DOCUMENT TYPE: English

LANGUAGE:

AUTHOR (S):

The synthesis of two rotationally restricted phenolic analogs I and II (R = CH2CH2NMe2) of the neurotransmitter serotonin have been accomplished. The syntheses of dihydropyranoindoles I and II (R = H), which formed the template for these targets, are outlined. These novel fused-indoles represent rotationally restricted phenolic analogs of 5-hydroxyindole. The reaction sequence of Claisen rearrangement of 3-Me, 4-(NO2) C6H3OCH2CH: CH2, followed by olefin hydroxylation, and intramol.

Mitsunobu reaction was used to form the fused dihydropyran rings. 135530-03-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and deprotection of)

135530-03-9 CAPLUS Boron, trihydro(3,7,8,9-tetrahydro-N,N-dimethylpyrano[3,2-e]indole-1ethanamine-N α)-, (T-4)- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

1991:492116 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 115:92116 TITLE:

Synthesis of a dihydropyrano[3,2-e]indole as a rotationally restricted phenolic analog of the

neurotransmitter serotonin

AUTHOR (S): Macor, John E.; Newman, Michael E. CORPORATE SOURCE: Cent. Res. Div., Pfizer, Inc., Groton, CT, 06340, USA SOURCE:

Tetrahedron Letters (1991), 32(28), 3345-8

CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English OTHER SOURCE(S): CASREACT 115:92116

Dihydropyranoindole I has been synthesized via a six step procedure involving a Claisen rearrangement of allyloxyindoleglyoxamide II. The novel heterocycle I represents a rotationally restricted phenolic analog of the neurotransmitter serotonin [3-(2-aminoethy1)-5-hydroxyindole].

135530-03-9P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and deprotection of)

135530-03-9 CAPLUS Boron, trihydro(3,7,8,9-tetrahydro-N,N-dimethylpyrano[3,2-e]indole-1ethanamine-Na)-, (T-4)- (9CI) (CA INDEX NAME)

ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

135530-02-89

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and intramol. Mitsunobu reaction of) 135530-02-8 CAPLUS

Boron, [3-{2-(dimethylamino)ethyl]-5-hydroxy-1H-indole-4-propanol-N3)trihydro-, (T-4)- (9CI) (CA INDEX NAME)

HO — (CH₂) 3
$$CH_2 - CH_2 - N - Me$$

HO — (CH₂) 3 Me

ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) 135530-02-8P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and intramol. Mitsunobu reaction of)

135530-02-8 CAPLUS

Boron, [3-[2-(dimethylamino)ethyl]-5-hydroxy-1H-indole-4-propanol-N3]trihydro-, (T-4)- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

1982:199969 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 96:199969

The partial syntheses of reserpiline and TITLE:

isoreserpiline AUTHOR(S): Sakai, Shinichiro; Saito, Naoki; Hirose, Naohiro;

Yamanaka, Etsuji Fac. Pharm. Sci., Chiba Univ., Chiba, 260, Japan CORPORATE SOURCE:

Heterocycles (1982), 17(Spec. Issue), 99-103 SOURCE:

CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal LANGUAGE: English

Reserviline (I, R = β -H) and isoreserviline (I, R = α -H) were synthesized through 5,6-dimethoxyindole derivative II (X = H2, O) and amine

synthon III which was already derived from natural oxindole alkaloids

and/or by the total syntheses. 81641-54-5P 81642-36-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

81641-54-5 CAPLUS

Boron, [5,6-dimethoxy-3-[2-(1-piperidinyl)ethyl]-1H-indole-N3]trihydro-, (T-4)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1973:147723 CAPLUS 78:147723

DOCUMENT NUMBER: Comparison of lithium aluminum hydride and diborane TITLE:

in the reduction of certain 3-indolylglyoxamides

AUTHOR (S): Littell, Ruddy; Allen, George R., Jr.

CORPORATE SOURCE: Lederle Lab. Div., Am. Cyanamid Co., Pea

Journal of Organic Chemistry (1973), 38(8), 1504-10 SOURCE:

CODEN: JOCEAH; ISSN: 0022-3263 DOCUMENT TYPE: Journal

LANGUAGE: English

AB The utility of LiAlH4 and diborane for the preparation of trypthamines fro

3-indolylglyoxamides, including 4-trifluoromethyl derivs., was studied. Diborane allows elaboration of the tryptamine, side-chain without

concomitant reduction of trifluoromethyl substituents, whereas these

are converted into Me substituents by LiAlH4 when reducing conditions are

sufficiently vigorous to give the tryptamine. Reduction of the glyoxamides

with diborane may be accompanied by reduction of th indolic enamine triad to

give indolines, an event not seen with LiAlH4. 1-Alkyl-3-

indolyglyoxamides are converted into the corresponding trypta- mines by diborane, whereas LiAlH reduction gives 1-alkyl-3-indolylglyco- lamines.

formation of a 3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indole was observed

in the LiAlH4 reduction of 5-methoxy-N,N,2-trimethyl-4-(trifluoromethyl)-3-

indolyglyoxamide. Diborane reduction of 3-indolecarboxylic acid and its ethyl

ester gave skatole as the major product.

38662-20-3P 38662-23-6P IT RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

38662-20-3 CAPLUS Boron, trihydro(N,N,1-trimethyl-1H-indole-3-ethanamine-Na)-, (T-4)-(9CI) (CA INDEX NAME)

Boron, trihydro(5-methoxy-N, N-dimethyl-1H-indole-3-ethanamine-Na)-,

(T-4) - (9CI) (CA INDEX NAME)

ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

81642-36-6 CAPLUS


Boron, trihydro(methyl 7-[2-(5,6-dimethoxy-1H-indol-3-yl)ethyl)-


4a, 5, 6, 7, 8, 8a-hexahydro-1-methyl-1H-pyrano[3, 4-c]pyridine-4-carboxylate}-, $[T-4-[1R-(1\alpha,4a\alpha,8a\alpha)]]$ (9CI) (CA INDEX NAME)

ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

=>

Uploading C:\Program Files\Stnexp\Queries\10539151\claim 36 XII1.str





chain nodes : 10 11 15 16 ring nodes : 1 2 3 4 5 6 7 8 9 ring/chain nodes : 12 13 14 chain bonds : 7-11 8-10 11-15 12-15 15-16 ring/chain bonds : 12-14 12-13 ring bonds : 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 exact/norm bonds : 5-7 6-9 7-8 8-9 12-14 12-13 12-15 15-16 exact bonds : 7-11 8-10 11-15 normalized bonds :

Match level :

1-2 1-6 2-3 3-4

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

L4 STRUCTURE UPLOADED

=> d L4 HAS NO ANSWERS L4 STR

Structure attributes must be viewed using STN Express query preparation.

=> s 14 ful

REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 16:38:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 39611 TO ITERATE

100.0% PROCESSED 39611 ITERATIONS

826 ANSWERS

SEARCH TIME: 00.00.01

L5 826 SEA SSS FUL L4

L6 309 L5

=> d ibib abs hitstr 309

L6 ANSWER 309 OF 309 CAPLUS COPYRIGHT 2007 ACS on STN 1938:6240 CAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 32:6240 ORIGINAL REFERENCE NO.: 32:939e-g TITLE: Diethylamide of the indole-3-carboxylic acid, β-indole-acetic acid, thionaphthene-3-carboxylic acid, and of the hydrogenated β -indolylacetic Wegler, Richard: Binder, Hans AUTHOR (5): SOURCE: Arch. Pharm. (1937), 275, 506-16 DOCUMENT TYPE: Journal LANGUAGE: Unavailable The following compds. were prepared and characterized: di-ethylamide of indolyl-3-carboxylic acid by interaction of Mg, MeI and indole, thereupon treatment of the resulting indolylmagnesium iodide with Et2NCOCl, C13H16ON2, m. 151-1.5° (picrate m. 129.5-30°); diethylamide of thionaphthene-3-carboxylic acid, C13H15ONS, oil, b11 220°; amide of indole-3-carboxylic acid, m. 200°; diethylamide of β-indolylacetic acid, C14H18ON, m. 101° (picrate m. $139-40^{\circ}$); β -indolylacetamide; diethylamide of 2,3-dihydro- and octahydro-3-indolylacetic acid (picrate of the dihydro compound m. 170-2°; salt of 2-nitro-1,3-diketohydrindene, yellow, m. 184°); picrate of the octahydro compound yellow, m. 177-8.5°); diethylamide of N-nitrosoindolyl-3-carboxylic acid, C13H15O2N3, m. 241-2°; diethylamide of N-aminoindolyl-3-carboxylic acid, C13H17ON3 m. 177.5-8°. IT 100722-27-8P, 3-Indoleacetamide, N, N-diethyl- 859965-26-7P , 3-Indoleacetamide, N,N-diethyl-, picrate RL: PREP (Preparation) (preparation of) 100722-27-8 CAPLUS 1H-Indole-3-acetamide, N, N-diethyl- (9CI) (CA INDEX NAME)

RN 859965-26-7 CAPLUS CN 3-Indoleacetamide, N,N-diethyl-, picrate (4CI) (CA INDEX NAME)

CM 1


CRN 100722-27-8 CMF C14 H18 N2 O L6 ANSWER 309 OF 309 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 88-89-1 CMF C6 H3 N3 O7

=>

Uploading C:\Program Files\Stnexp\Queries\10539151\claim 36 XII1_a.str




chain nodes : 10 11 15 16 17 ring nodes : 1 2 3 4 5 6 7 8 9 ring/chain nodes : 12 13 14 chain bonds : 7-11 8-10 11-15 12-15 15-16 ring/chain bonds : 12-14 12-13 ring bonds : 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 exact/norm bonds : 5-7 6-9 7-8 8-9 12-14 12-13 12-15 15-16 exact bonds : 7-11 8-10 11-15 normalized bonds : 1-2 1-6 2-3 3-4

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom

L7 STRUCTURE UPLOADED

=> d L7 HAS NO ANSWERS L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 17 full sub=15
 REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SUBSET SEARCH INITIATED 16:40:51 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 826 TO ITERATE

100.0% PROCESSED 826 ITERATIONS SEARCH TIME: 00.00.01

122 ANSWERS

L8

122 SEA SUB=L5 SSS FUL L7

SUBSET IS IGNORED AS A SCOPE FOR THIS SEARCH L9 69 L8

=> d ibib abs hitstr 69

L9 ANSWER 69 OF 69 CAPLUS COPYRIGHT 2007 ACS ON STN ACCESSION NUMBER: 1955:78071 CAPLUS DOCUMENT NUMBER: 49:78071 ORIGINAL REFERENCE NO.: 49:14810g-i,14811a

ORIGINAL REFERENCE NO.: 49:14810g-1,14811a
TITLE: (5-Benzyloxy-3-indolyl)alkanamides

INVENTOR(S): Speeter, Merrill E. PATENT ASSIGNEE(S): Upjohn Co.

DOCUMENT TYPE: Patent
LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

APPLICATION NO. DATE PATENT NO. KIND DATE 19520401 19541026 US 1952-279931 US 2692882 For diagram(s), see printed CA Issue. I (X is Ph, halophenyl, lower alkoxyphenyl, or lower alkylphenyl; Y is H, Ph, halophenyl, lower alkoxyphenyl, or lower alkylphenyl; R' and R'' are or lower alkyl; n is 0 or 1; and 2 is a secondary amine radical) are prepared by the following exemplary procedure. A Grignard reagent from 4.25 g. MeI and 2.4 g. Mg in 200 ml. Et20 added to 5.5 g. 5-benzyloxyindole in 200 ml. Et20, the solution refluxed 30 min., cooled in an ice-bath, 5.9 g. ClCH2CONMeCH2Ph in 200 ml. Et2O added, the mixture stirred, the Et20 distilled off, the residue warmed 3 hrs. on a steam bath, cooled, about 500 ml. Et20 added, then, with vigorous stirring, 5 ml. AcOH and 95 ml. H2O, the mixture allowed to stand overnight, and the product filtered and recrystd. gives 7.5 g. 2-(5-benzyloxy-3-indolyl)-N-benzyl-Nmethylacetamide, m. 151-2° (from iso-PrOH). Similarly prepared: in 69% yield, the N,N-di-PhCH2 analog, m. 156-7°; and in 30% yield, 2+(5-benzyloxy-3-indolyl)benzylacetamide, m. 185-6°. 725227-53-2P, 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-methyl-857776-54-6P, 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-Nisopropyl- 857776-60-4P, 3-Indoleacetamide, N,N-dibenzyl-5-(benzyloxy) - 872786-56-6P, Indole, 5-(benzyloxy)-3-(piperidinocarbonylmethyl)-

3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-methyl- (5CI) (CA INDEX

RL: PREP (Preparation) (preparation of) 725227-53-2 CAPLUS

RN 857776-54-6 CAPLUS


CN NAME) L9 ANSWER 69 OF 69 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-isopropyl- (5CI) (CA INDEX NAME)

RN 857776-60-4 CAPLUS
CN 3-Indoleacetamide, N,N-dibenzyl-5-(benzyloxy)- (5CI) (CA INDEX NAME)

RN 872786-56-6 CAPLUS
CN Piperidine, 1-[[5-(benzyloxy)-3-indolyl]acetyl]- (5CI) (CA INDEX NAME)

=>

Uploading C:\Program Files\Stnexp\Queries\10539151\claim 36 triple bond.str




chain nodes : 10 11 15 16 17 18 ring nodes : 1 2 3 4 5 6 7 8 9 ring/chain nodes : 12 13 14 chain bonds : 7-11 8-10 11-15 12-15 16-17 16-18 ring/chain bonds : 12-14 12-13 ring bonds : 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 exact/norm bonds : 5-7 6-9 7-8 8-9 12-14 12-13 12-15 16-18 exact bonds : 7-11 8-10 11-15 16-17 normalized bonds : 1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom

L10 STRUCTURE UPLOADED

=> d L10 HAS NO ANSWERS L10 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 110 full
 REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 16:47:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1115 TO ITERATE

100.0% PROCESSED 1115 ITERATIONS


0 ANSWERS

SEARCH TIME: 00.00.01

L11 0 SEA SSS FUL L10

L12 0 L11

=> Uploading C:\Program Files\Stnexp\Queries\10539151\claim 36 double bond.str



chain nodes :

10 11 15 16 17 18

ring nodes :

1 2 3 4 5 6 7 8 9
ring/chain nodes:
12 13 14
chain bonds:
7-11 8-10 11-15 12-15 16-17 16-18
ring/chain bonds:
12-14 12-13
ring bonds:
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds:
5-7 6-9 7-8 8-9 12-14 12-13 12-15 16-18
exact bonds:
7-11 8-10 11-15 16-17
normalized bonds:
1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom

L13 STRUCTURE UPLOADED

=> d L13 HAS NO ANSWERS L13 STR

Structure attributes must be viewed using STN Express query preparation.

=> s 113 full
 REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

10/539,151 02/21/2007

FULL SEARCH INITIATED 16:48:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 17377 TO ITERATE

100.0% PROCESSED 17377 ITERATIONS


O ANSWERS

SEARCH TIME: 00.00.01

L14 0 SEA SSS FUL L13

L15 0. L14

=>
Uploading C:\Program Files\Stnexp\Queries\10539151\claim 36 CN.str



chain nodes : 10 11 15 16 ring nodes :

1 2 3 4 5 6 7 8 9

ring/chain nodes :

12 13 14

chain bonds :

7-10 10-11 11-12 15-16

ring/chain bonds :

12-13 12-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

5-7 6-9 7-8 8-9 11-12 12-13 12-14 15-16

exact bonds : 7-10 10-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom

L16 STRUCTURE UPLOADED


=> d

L16 HAS NO ANSWERS

L16

STR

9 ANSWERS



Structure attributes must be viewed using STN Express query preparation.

=> s 116 full
 REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 16:53:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 10023 TO ITERATE

100.0% PROCESSED 10023 ITERATIONS

SEARCH TIME: 00.00.01

L17 9 SEA SSS FUL L16

L18 1 L17

=> d ibib abs hitstr L18

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

2006:54890 CAPLUS 144:150235

TITLE:

Preparation of

1,3-dihydro-1-(phenylsulfonyl)-2H-indol-

2-ones and related compounds as vasopressin V1B receptor modulators

INVENTOR(S):

Lubisch, Wilfried; Oost, Thorsten; Wernet, Wolfgang; Unger, Liliane; Hornberger, Wilfried; Geneste, Herve

US 2004-587407P

P 20040713

PATENT ASSIGNEE (S):

PCT Int. Appl., 130 pp. CODEN: PIXXD2

Abbott Gmbh & Co.Kg, Germany

SOURCE: DOCUMENT TYPE:

Patent German

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

	PATENT NO.					KIND DATE				APPL	ICAT		DATE					
	WO 2006005609					A2 20060119			WO 2005-EP7631						20050713			
wo	2006	0056	09		EA		2006	0316										
	W;	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BĢ,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KP,	KR,	ΚZ,	
		LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	
		NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	
		SL,	SM,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	Yυ,	
		ZA,	ZM,	ZW														
	RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	ΗU,	IE,	
		IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	
		CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	GH,	
		GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	52,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
					RU,													
DE	1020	0403	3834		Al		2006	0202		DE 2	004-	1020	0403	3834	2	0040	713	
PRIORIT	Y APP	LN.	INFO	.:						DE 2	004-	1020	0403	3834	A 2	0040	713	

OTHER SOURCE(S):

MARPAT 144:150235

$$R^1$$
 R^3
 R^3

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

873955-55-6 CAPLUS Piperidine, 1-[[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(4methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]acetyl]-4-(4-propyl-1piperazinyl) - (9CI) (CA INDEX NAME)

873955-56-7 CAPLUS Piperidine, 1-[[5-cyano-3-(2-ethoxyphenyl)-1-[(2-fluorophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]acetyl]-4-(4-propyl-1-piperazinyl)+ (9CI) (CA INDEX NAME)

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Title compds. I (A = (un)substituted aryl; B = (un)substituted aromatic, etc.; R1 = H, alkyl, OH, etc.; R2 = H, alkyl, O-alkyl, etc.; R3 = -Z-Y-X-W; W = alkylene, alkylene+O-alkylene, etc.; X = CO, SO2, C=NH, etc.; Y = pyrrolidinyl, pyridinyl, azepanyl, etc.) and their pharmaceutically acceptable salts were prepared for example, phenylsulfonylindolone II was prepared from 5-chloroisatin in 4-steps.

vasopressin V1B receptor binding assays, 9-examples of compds. I exhibited

Ki values <100 nM.

873955-53-4P 873955-54-5P 873955-55-6P 873955-56-7P 873955-57-8P 873955-58-9P

873955-59-0P 873955-71-6P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(preparation of phenylsulfonylindolones and related compds. for the treatment of vasopressin or oxytocin dependent diseases)

873955-53-4 CAPLUS

Piperidine, 1-{[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]acetyl]-4-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

873955-54-5 CAPLUS

Piperidine, 1-[[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]acetyl]-4-(4-propyl-1piperazinyl) - (9CI) (CA INDEX NAME)

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

873955-57-8 CAPLUS Piperidine, 1-[[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]acetyl]-4-(4-propyl-1piperazinyl) - (9CI) (CA INDEX NAME)

873955-58-9 CAPLUS Piperidine, 1-{{5-cyano-1-{(2,4-difluorophenyl)sulfonyl}-3-(2+ ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]acetyl]-4-(4-propyl-1piperazinyl) - (9CI) (CA INDEX NAME)

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 873955-59-0 CAPLUS
CN Piperidine, 1-[[1-[(4-chlorophenyl)sulfonyl]-5-cyano-3-(2-ethoxyphenyl)2,3-dihydro-2-oxo-1H-indol-3-yl]acetyl}-4-(4-propyl-1-piperazinyl)- (9CI)
(CA INDEX NAME)

RN 873955-71-6 CAPLUS
CN Piperidine, 1-[[5-cyano-3-(2-ethoxyphenyl)-1-[(4-fluorophenyl)sulfonyl]2,3-dihydro-2-oxo-1H-indol-3-yl]acetyl]-4-(4-propyl-1-piperazinyl)- (9CI)
(CA INDEX NAME)

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of phenylsulfonylindolones and related compds. for the treatment of vasopressin or oxytocin dependent diseases)

RN 873955-87-4 CAPLUS CN Piperidine, 1-[[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-

=>

Uploading C:\Program Files\Stnexp\Queries\10539151\claim 36 ester.str

chain nodes : 10 11 12 14 15 16 ring nodes : 1 2 3 4 5 6 7 8 9 ring/chain nodes : 13 18 19 chain bonds : 7-11 8-10 11-12 12-13 14-15 15-16 ring/chain bonds : 13-18 13-19 ring bonds : 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 exact/norm bonds : 5-7 6-9 7-8 8-9 12-13 13-18 13-19 14-15 15-16 exact bonds : 7-11 8-10 11-12 normalized bonds : 1-2 1-6 2-3 3-4 4-5 5-6


G1:H,O

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:CLASS 19:CLASS

L19 STRUCTURE UPLOADED

=> d L19 HAS NO ANSWERS L19 STR



G1 H,O

Structure attributes must be viewed using STN Express query preparation.

=> s l19 full
 REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 17:00:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 325244 TO ITERATE

100.0% PROCESSED 325244 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.02

L20 3 SEA SSS FUL L19

ABS ----- GI and AB

L21 1 L20

=> d ibib abs histr
'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ALL ------ BIB, AB, IND, RE

APPS ----- AI, PRAI

BIB ----- AN, plus Bibliographic Data and PI table (default)

CAN ----- List of CA abstract numbers without answer numbers

CBIB ----- AN, plus Compressed Bibliographic Data

CLASS ----- IPC, NCL, ECLA, FTERM

DALL ----- ALL, delimited (end of each field identified)

DMAX ----- MAX, delimited for post-processing

FAM ----- AN, PI and PRAI in table, plus Patent Family data

FBIB ----- AN, BIB, plus Patent FAM

10/539,151

```
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
             SCAN must be entered on the same line as the DISPLAY,
             e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS
IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels
OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels
SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations
HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
             containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
             its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
             structure diagram, plus NTE and SEQ fields
FHITSTR ---- First HIT RN, its text modification, its CA index name, and '
             its structure diagram
FHITSEQ ---- First HIT RN, its text modification, its CA index name, its
             structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs
```

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI, AU; BIB, ST; TI, IND; TI, SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number. ENTER DISPLAY FORMAT (BIB):ibib

02/21/2007

L21 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:322670 CAPLUS 135:122435

DOCUMENT NUMBER:

TITLE: inhibitors A novel series of thromboxane A2 synthetase

with free radical scavenging and anti-peroxidative activities

AUTHOR (S):

Kamiya, Shoji; Shirahase, Hiroaki; Nakamura, Shohei; Kanda, Mamoru; Matsui, Hiroshi; Yoshimi, Akihisa; Kasai, Masayasu; Takahashi, Kenji; Kurahashi,

Kazuyoshi CORPORATE SOURCE:

Research Laboratories, Kyoto Pharmaceutical

SOURCE:

Industries, Ltd., Kyoto, 604-8444, Japan Chemical & Pharmaceutical Bulletin (2001), 49(5),

CODEN: CPBTAL; ISSN: 0009-2363 Pharmaceutical Society of Japan

PUBLISHER: DOCUMENT TYPE:

Journal

English LANGUAGE:

OTHER SOURCE(S):

CASREACT 135:122435

REFERENCE COUNT: THIS

THERE ARE 22 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> d ibib abs hitstr L21

L21 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

2001:322670 CAPLUS ACCESSION NUMBER: DOCUMENT NUMBER:

TITLE:

135:122435 A novel series of thromboxane A2 synthetase

inhibitors

AUTHOR (S):

SOURCE:

with free radical scavenging and anti-peroxidative

Kamiya, Shoji; Shirahase, Hiroaki; Nakamura, Shohei;

Kanda, Mamoru; Matsui, Hiroshi; Yoshimi, Akihisa; Kasai, Masayasu; Takahashi, Kenji; Kurahashi,

Kazuyoshi

CORPORATE SOURCE:

Research Laboratories, Kyoto Pharmaceutical Industries, Ltd., Kyoto, 604-8444, Japan Chemical & Pharmaceutical Bulletin (2001), 49(5),

563-571 CODEN: CPBTAL; ISSN: 0009-2363 Pharmaceutical Society of Japan

PUBLISHER: DOCUMENT TYPE:

Journal English LANGUAGE:

OTHER SOURCE(S): CASREACT 135:122435

AB A novel series of indoline derivs. with imidazole and carboxyl moieties were synthesized and evaluated for their thromboxane A2 (TXA2) synthetase inhibiting, radical scavenging and anti-peroxidative activities. Among the compds. synthesized, 3-{5-substituted-3-{2-(imidazol-1yl)ethyl]indolin-1-yl)propionic acids showed free radical scavenging activity and inhibitory effects on lipid-peroxidn, of rat brain

and on arachidonate-induced TXA2-dependent aggregation of rabbit platelets. The anti-platelet and anti-peroxidative activities were related to the lipophilicity of the 5-substituent. The 5-hexyloxy derivative

(I) showed about 35-fold higher inhibitory activity on TXA2 synthesis than

that of ozagrel and about 100-fold higher activity on lipid peroxidn. than

that of α -tocopherol. Compound I showed in vivo anti-thrombotic effect in mice and ex vivo anti-peroxidative activity in rats.

350683-18-0P RL: BAC (Biological activity or effector, except adverse); BSU

study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL

(Biological study); PREP (Preparation) (preparation of indoline thromboxane A2 synthetase inhibitors with

free

radical scavenging and anti-peroxidative activities)

350683-18-0 CAPLUS

1H-Indole-5-carboxylic acid, 2,3-dihydro-3-[2-(1H-imidazol-1-yl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L21 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

●2 HC1

IT 350683-34-0P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of indoline thromboxane A2 synthetase inhibitors with

free

radical scavenging and anti-peroxidative activities)

350683-34-0 CAPLUS RN 1H-Indole-1,5-dicarboxylic acid,

2,3-dihydro-3-(2-(1H-imidazol-1-yl)ethyl)-, 1-(1,1-dimethylethyl) 5-ethyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT: THIS

THERE ARE 22 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=>

Uploading C:\Program Files\Stnexp\Queries\10539151\claim 36 XXI.str

chain nodes:
10 11 12 13 17
ring nodes:

1 2 3 4 5 6 7 8 9

ring/chain nodes :

14 15 16 chain bonds:

3-10 7-12 10-11 12-13 13-14 13-17

ring/chain bonds :

14-15 14-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

5-7 6-9 7-8 8-9 13-14 13-17 14-15 14-16

exact bonds :

3-10 7-12 10-11 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L22 STRUCTURE UPLOADED

=> d L22 HAS 1

L22 HAS NO ANSWERS

L22

STR

Structure attributes must be viewed using STN Express query preparation.

=> s 122 full
 REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 17:03:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 668 TO ITERATE

100.0% PROCESSED

668 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L23

O SEA SSS FUL L22

L24

0 L23

=> Uploading C:\Program Files\Stnexp\Queries\10539151\claim 35 XXIstarstar.str

chain nodes :


```
10 11 12 13 17
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
14 15 16
chain bonds :
3-10 7-12 10-11 12-13 13-14 13-17
ring/chain bonds :
14-15 14-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 8-9 10-11 13-14 13-17 14-15 14-16
exact bonds :
3-10 7-12 12-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
```

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L25 STRUCTURE UPLOADED

=> d L25 HAS NO ANSWERS L25 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 125 full
 REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

3 ANSWERS

FULL SEARCH INITIATED 17:04:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11168 TO ITERATE

100.0% PROCESSED 11168 ITERATIONS

SEARCH TIME: 00.00.01

L26 3 SEA SSS FUL L25

L27 1 L26

=> d ibib abs hitstr

L27 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2005:141029 CAPLUS 142:240430

DOCUMENT NUMBER: TITLE:

Preparation of heterocyclic compounds as hepatitis C

JP 2003-288296

JP 2003-288298

A 20030806

A 20030806

virus polymerase inhibitors

INVENTOR(S): Oka, Takahiro; Yata, Shinji; Ikegashira, Kazutaka; Noji, Satoru; Akaki, Tatsuo; Hirashima, Shintaro; Niwa, Yasushi; Ando, Izuru; Sato, Toshihiro

PATENT ASSIGNEE (S): SOURCE:

Japan Tobacco Inc., Japan PCT Int. Appl., 467 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.					KIND		DATE			APPLICATION NO.				DATE			
					Al		20050217			WO 2004-JP11640				20040806			
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	ĢΒ,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	ΜX,	ΜZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
		AZ,	BY,	KG,	ΚZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,
		SI,	SK,	TR,	BF,	BJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,
		SN,	TD,	TG													

OTHER SOURCE(S):

GI

PRIORITY APPLN. INFO.:

MARPAT 142:240430

$$G^2$$
 G^3
 G^4
 G^9
 G^5
 G^5
 G^6
 G^7
 G^6
 G^7
 G^7

AB The title compds. I [G1 = CR1, N; G2 = CR2, N; G3 = CR3, N; G4 = CR4, N; G5, G6, G8, G9 = C, N; G7 = O, etc.; R1 - R4 = H, halo, etc.; R5, R6 = H, halo, etc.; ring Cy = (un) substituted cycloalkyl, etc.; ring A = aryl, etc.; X = H, halo, etc.] are prepared Thus, 2-(4-(2-(4-chlorophenyl)-5-(2oxopyrrolidin-1-yl)benzyloxy|phenyl]-3-cyclohexyl-1-methyl-1-H-indole-6-

(Continued) L27 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

REFERENCE COUNT: THIS

THERE ARE 51 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L27 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued) carboxylic acid was prepd. in a multistep process starting from Me 3-aminobenzoate. In an in vitro test for hepatitis C virus polymerase inhibiting activity, compds. of this invention showed IC50 values of < 0.01 μM to < 1 μM . Formulations are given.

IT 844895-87-0P 844895-88-1P 844895-90-5P RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as hepatitis C virus polymerase

inhibitors) 844895-87-0 CAPLUS

1H-Indole-5-carboxylic acid, 1-cyclohexyl-3-(2-(diethylamino)-2-oxoethyl)-

2-phenyl- (9CI) (CA INDEX NAME)

844895-88-1 CAPLUS 1H-Indole-5-carboxylic acid, 1-cyclohexyl-3-[2-(diethylamino)-2-oxoethyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

844895-90-5 CAPLUS 1H-Indole-5-carboxylic acid, 1-cyclohexyl-3-[2-(dimethylamino)-2-oxoethyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME) =>

Uploading C:\Program Files\Stnexp\Queries\10539151\claim 36 XX7.str

chain nodes :
10 11 15
ring nodes :

1 2 3 4 5 6 7 8 9

ring/chain nodes :

12 13 14 chain bonds

chain bonds :

7-10 10-11 11-12

ring/chain bonds : ,

12-13 12-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

5-7 6-9 7-8 8-9 12-13 12-14

exact bonds :

7-10 10-11 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom

L28 STRUCTURE UPLOADED

=> d

L28 HAS NO ANSWERS

L28

STR

Structure attributes must be viewed using STN Express query preparation.

=> s 128 full REG1stRY INITIATED Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 17:05:56 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -257 TO ITERATE

100.0% PROCESSED 257 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L29 . O SEA SSS FUL L28

L30 0-L29

=>

---Logging off of STN---

=> Executing the logoff script...

=> LOG Y

SINCE FILE TOTAL COST IN U.S. DOLLARS ENTRY SESSION FULL ESTIMATED COST 0.47 1677.66

Searched by Jason M. Nolan, Ph.D.

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY

TOTAL SESSION

CA SUBSCRIBER PRICE

0.00

-9.36

STN INTERNATIONAL LOGOFF AT 17:06:02 ON 21 FEB 2007

STN - Cas react

Claim 24

```
chain nodes :
10 11 12 25 26 27 31 32 33 34
ring nodes :
1 2 3 4 5 6 7 8 9 16 17 18 19 20 21 22 23 24
ring/chain nodes :
13 14 15 28 29 30
chain bonds :
7-11 8-10 9-31 11-12 12-13 22-26 23-25 24-32
                                              26-27. 27-28 33-34
ring/chain bonds :
13-14 13-15 28-29 28-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 16-17 16-21 17-18 18-19 19-20
20-21 20-22 21-24 22-23 23-24
exact/norm bonds :
5-7 6-9 7-8 8-9 13-14 13-15 20-22 21-24 22-23 23-24 24-32 28-29 28-30
33-34
exact bonds :
7-11 8-10 9-31 11-12 12-13 22-26 23-25 26-27 27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21
```

G1:Si,Cb,Ak,[*1]

```
Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS
fragments assigned product role:
containing 16
fragments assigned reactant/reagent role:
containing 1
node mappings:
```

9:24 8:23 7:22 5:20 6:21

STRUCTURE UPLOADED L1

=> d

L1 HAS NO ANSWERS

L1

STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT * Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 10:07:00 FILE 'CASREACT'

SCREENING COMPLETE -45295 REACTIONS TO VERIFY FROM 3761 DOCUMENTS

31 DOCS

100.0% DONE

45295 VERIFIED 111 HIT RXNS

SEARCH TIME: 00.00.05

31 SEA SSS FUL L1 (111 REACTIONS) L2

=> d ibib abs hit 1-31

(Continued)

(Continued)

```
L2 ANSWER 1 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                        144:192408 CASREACT
ACCESSION NUMBER:
TITLE:
                         Facile Construction of the Pentacyclic Framework of
                         Subincanadine B. Synthesis of 20-Deethylenylated
                         Subincanadine B and 19,20-Dihydrosubincanadine B
                         Liu, Yanqin; Luo, Shengjun; Fu, Xingnian; Fang, Fang;
AUTHOR (5):
                         Zhuang, Zeyang; Xiong, Wanting; Jia, Xueshun; Zhai,
CORPORATE SOURCE:
                         Shanghai Institute of Organic Chemistry, Chinese
                         Academy of Sciences, Shanghai, 200032, Peop.
                         China
                         Organic Letters (2006), 8(1), 115-118
SOURCE:
                         CODEN: ORLEF7; ISSN: 1523-7060
                         American Chemical Society
PUBLISHER:
DOCUMENT TYPE:
                         Journal
LANGUAGE:
                         English
GI
                                                  II
```

AB We describe a facile approach for effectively constructing the pentacyclic

framework of subincanadine B. The seven-step assembly of tetracyclic ketone I featured Michael addition, Pictet-Spengler cyclization, and Dieckmann condensation. From this key ketone intermediate, two analogs

RECORD. ALL CITATIONS AVAILABLE IN THE RE

subincanadine B, i.e., 20-deethylenylated subincanadine B (II·Cl-; R = H) and 19,20-dihydrosubincanadine B (II·Cl-; R = Et), were synthesized in four steps, resp.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR

FORMAT

οf

RX(5) OF 68 ...R + T ===> U...

Ph Br

T

(5)

Ph

Br

(5)

Ph

RX (5)

STAGE (1)

RGT V 7646-69-7 NaH

SOL 68-12-2 DMF

CON room temperature

STAGE (2)

RCT R 15741-71-6

SOL 68-12-2 DMF

CON 1 hour, room temperature

STAGE (3)

RCT T 100-39-0

CON overnight, 55 deg C

PRO U 874916-37-7

ANSWER 2 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

RCT K 28383-23-5, M 74-88-4

RGT O 7646-69-7 NaH PRO N 1640-04-6

RX (6)

RX(7) OF 56

L2 ANSWER 1 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

L2 ANSWER 2 OF 31 CASREACT COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 143:278414 CASREACT TITLE: SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist AUTHOR (S): Sard, Howard; Kumaran, Govindaraj; Morency, Cynthia; Roth, Bryan L.; Toth, Beth Ann; He, Ping; Shuster, Louis CORPORATE SOURCE: Organix, Inc., Woburn, MA, 01801, USA Bioorganic & Medicinal Chemistry Letters (2005) SOURCE: 15(20), 4555-4559 CODEN: BMCLE8; ISSN: 0960-894X PUBLISHER: Elsevier B.V. DOCUMENT TYPE: Journal LANGUAGE: English AB An SAR study of psilocybin and psilocin derivs. reveals that 1-methylpsilocin is a selective agonist at the h5-HT2C receptor. The corresponding phosphate derivative, 1-methylpsilocybin, shows efficacy animal model for obsessive-compulsive disorder, as does 4-fluoro-N, N-dimethyltryptamine. These results suggest a new area for development of novel 5-HT2C agonists with applications for drug discovery. REFERENCE COUNT: THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE **FORMAT** RX(6) OF 56 M ===> N... H3C--- I

L2 ANSWER 2 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

R YIELD 78%

RX(6) RCT K 28383-23-5, M 74-88-4 RGT O 7646-69-7 NaH PRO N 1640-04-6

RX(8) RCT N 1640-04-6 RGT S 1333-74-0 H2 PRO R 1465-16-3 CAT 7440-05-3 Pd

RX(34) OF 56 COMPOSED OF RX(7), RX(9) RX(34) K + P ===> U L2 ANSWER 2 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

U YIELD 67%

RX(7) RCT K 28383-23-5, P 542-69-8 PRO Q 879485-07-1 NTE no experimental detail

RX(9) RCT Q 879485-07-1 RGT S 1333-74-0 H2 PRO U 864186-05-0 CAT 7440-05-3 Pd

RX(49) OF 56 COMPOSED OF RX(6), RX(8), RX(10) RX(49) K + M ===> V

L2 ANSWER 2 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

V YIELD 12%

RX(6) RCT K 28383-23-5, M 74-88-4 RGT O 7646-69-7 NaH PRO N 1640-04-6

RX(8) RCT N 1640-04-6 RGT S 1333-74-0 H2 PRO R 1465-16-3 CAT 7440-05-3 Pd

RX(10) RCT R 1465-16-3

STAGE(1) RGT W 1623-08-1 (PhCH2O)2P(O)OH, X 4111-54-0 LiN(Pr-i)2

STAGE (2) RGT S 1333-74-0 H2 CAT 7440-05-3 Pd PRO V 18483-72-2

RX(51) OF 56 COMPOSED OF RX(7), RX(9), RX(11)

RX(51) K + P ===> Y

L2 ANSWER 2 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

Y YIELD 26%

RX(7) RCT K 28383-23-5, P 542-69-8 PRO Q 879485-07-1 NTE no experimental detail

RX(9) RCT Q 879485-07-1 RGT S 1333-74-0 H2 PRO U 864186-05-0 CAT 7440-05-3 Pd

RX(11) RCT U 864186-05-0

STAGE(1) RGT W 1623-08-1 (PhCH2O)2P(0)OH, X 4111-54-0 LiN(Pr-i)2 STAGE(2) RGT S 1333-74-0 H2 CAT 7440-05-3 Pd

PRO Y 864186-06-1

(Continued)

L2 ANSWER 3 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

143:26761 CASREACT

TITLE:

Convenient Synthesis of Substituted Piperidinones

from

 α, β -Unsaturated Amides: Formal Synthesis of Deplancheine, Tacamonine, and Paroxetine Takasu, Kiyosei; Nishida, Naoko; Tomimura, Akiko; AUTHOR (S): Ihara, Masataka

CORPORATE SOURCE:

Department of Organic Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan

SOURCE:

Journal of Organic Chemistry (2005), 70(10), 3957-3962

PUBLISHER:

CODEN: JOCEAH; ISSN: 0022-3263 American Chemical Society

DOCUMENT TYPE: LANGUAGE:

Journal English

ĢĪ

An intermol. aza-double Michael reaction leading to functionalized piperidin-2-ones from simple starting materials has been developed. The method allows α, β -unsatd. amides to be used as a synthon of the piperidine nucleus. For example, reacting H2C: CHCONHR1 (R1 = PhCH2, cyclohexyl, 2-indolylethyl, 2-PhCH2CH2) with TMSI/HDMS or TBSOTf/NEt3

gave the piperidinones I in good to excellent yields. In addition, the utility of

this methodol. is demonstrated by its application to a formal synthesis

the indolo{2,3-a}quinolizidine alkaloids, (t)-deplancheine, (±)-tacamonine, and the antidepressant paroxetine. As an illustration, I (R1 = 2-indolylethyl) was converted to (indolo[2,3a]quinolizidinyl)ethanone II which has previously been transformed into (±)-deplancheine.

REFERENCE COUNT: THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

THERE ARE 54 CITED REFERENCES AVAILABLE FOR

FORMAT

RX(10) OF 87 ...S + 2 AC ===> AD... L2 ANSWER 3 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

YIELD 96%

RX (10) S 853063-74-8, AC 24424-99-5 RGT I 121-44-8 Et3N

PRO AD 853063-66-8

CAT 1122-58-3 4-DMAP

CON 1 hour, room temperature

RX(39) OF 87 COMPOSED OF RX(10), RX(11) RX(39) S + 2 AC ===> AF

(Continued) L2 ANSWER 3 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

AF YIELD 86%

RX(10) RCT S 853063-74-8, AC 24424-99-5

I 121-44-8 Et3N RGT PRO AD 853063-66-8

CAT 1122-58-3 4-DMAP

CON 1 hour, room temperature

RX(11)

RCT AD 853063-66-8 RGT AG 124-41-4 NaOMe PRO AF 853063-67-9

SOL 67-56-1 MeOH CON 20 minutes, 0 deg C ANSWER 3 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

RX(52) OF 87 COMPOSED OF RX(10), RX(11), RX(16) RX(52) S + 2 AC ===> AV

YIELD 67%

RCT S 853063-74-8, AC 24424-99-5 RX(10)

RGT I 121-44-8 Et3N PRO AD 853063-66-8

CAT 1122-58-3 4-DMAP

CON 1 hour, room temperature

RX(11) RCT AD 853063-66-8 RGT AG 124-41-4 NaOMe PRO AF 853063-67-9 SOL 67-56-1 MeOH

PUBLISHER:

ANSWER 3 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) CON 20 minutes, 0 deg C RCT AF 853063-67-9 RX (16) STAGE (1)

RGT AW 16949-15-8 LiBH4, AX 22560-16-3 Superhydride SOL 109-99-9 THF CON 6 hours, room temperature

RGT AO 7732-18-5 Water

PRO AV 853063-70-4

L2 ANSWER 4 OF 31 CASREACT COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 142:348129 CASREACT

Tryptamine and homotryptamine-based sulfonamides as TITLE: potent and selective inhibitors of 15-lipoxygenase Weinstein, David S.; Liu, Wen; Gu, Zhengxiang; AUTHOR (S): Langevine, Charles; Ngu, Khehyong; Fadnis, Leena; Combs, Donald W.; Sitkoff, Doree; Ahmad, Saleem; Zhuang, Shaobin; Chen, Xing; Wang, Feng-Lai;

Loughney, Deborah A.; Atwal, Karnail S.; Zahler, Robert; Macor,

John E.; Madsen, Cort S.; Murugesan, Natesan Bristol-Myers Squibb Pharmaceutical Research CORPORATE SOURCE: Institute, Bristol-Myers Squibb, Princeton, NJ,

08543,

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(5), 1435-1440

Elsevier B.V.

CODEN: BMCLE8; ISSN: 0960-894X

DOCUMENT TYPE: Journal LANGUAGE: English A series of inhibitors of mammalian 15-lipoxygenase based on tryptamine

and homotryptamine scaffolds is described. Compds. with aryl at C-2 of the indole core of tryptamine and homotryptamine sulfonamides

proved to be potent inhibitors of the isolated enzyme. Selected compds. also demonstrated desirable inhibition selectivities over isoenzymes 5and P-12-LO.

REFERENCE COUNT: THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RX(142) OF 196 COMPOSED OF RX(26), RX(35), RX(66) RX(142) BF + BY + DN ===> DO

ANSWER 4 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

YIELD 97%

RX (26) RCT BF 15741-71-6

BH 39416-48-3 Pyridinium tribromide PRO BG 192182-46-0

SOL 109-99-9 THF, 67-66-3 CHC13

NTE regioselective

RX (35) RCT BG 192182-46-0, BY 98437-24-2

RGT Q 497-19-8 Na2CO3, BN 7447-41-8 LiCl PRO BZ 849216-93-9

CAT 14221-01-3 Pd(PPh3)4

SOL 64-17-5 EtOH, 108-88-3 PhMe

NTE Suzuki reaction

RCT BZ 849216-93-9, DN 74-88-4 RX (66)

RGT DP 7646-69-7 NaH PRO DO 70369-20-9

SOL 68-12-2 DMF

L2 ANSWER 5 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 142:298020 CASREACT

TITLE: Synthesis and cytotoxic activity of carboxamide

derivatives of benzo[b][1,6]naphthyridin-(5H)ones Deady, Leslie W.; Rogers, Michael L.; Zhuang, Li; AUTHOR (S):

Baguley, Bruce C.; Denny, William A.

CORPORATE SOURCE: Chemistry Department, La Trobe University, 3086,

SOURCE:

Bioorganic & Medicinal Chemistry (2005), 13(4), 1341-1355 CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

A previous reaction leading to 2-substituted 6-methyl-1-oxo-1,2dihydrobenzo[b][1,6]naphthyridine-4-carboxylic acids has been extended to encompass a broad range of 2-substituents. Carboxamides, e.g., I, particularly 4-N-(2-(dimethylamino)ethyl), were tested for growth inhibitory properties. Potent cytotoxicity against murine P388 leukemia and Lewis lung carcinoma (LLTC) was retained for compds. bearing a remarkably diverse range of 2-substituents with a number having IC50

values <10 nM. Five of the compds. were tested in vivo against s.c. colon 38 tumors in mice; a single dose (1.8 mg/kg) proved curative for the 2-(4-fluorophenyl) derivative, a further increase in potency over the

effective 2-Me analog reported previously. THERE ARE 13 CITED REFERENCES AVAILABLE FOR REFERENCE COUNT: 13

THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

RX(56) OF 186 ...AQ + BQ + 2 BO ===> CB...

FORMAT

ANSWER 5 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

CB YIELD 62%

RCT AQ 627093-64-5, BQ 530-62-1 RX (56)

> STAGE(1) SOL 123-91-1 Dioxane CON 48 hours, reflux

ANSWER 6 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

141:424159 CASREACT ACCESSION NUMBER:

Novel 5-HT7 Receptor Inverse Agonists. Synthesis and TITLE:

Molecular Modeling of Arylpiperazine- and 1,2,3,4-Tetrahydroisoquinoline-Based Arylsulfonamides

Vermeulen, Erik S.; Van Smeden, Marjan; Schmidt, Anne AUTHOR (S):

W.; Sprouse, Jeffrey S.; Wikstroem, Haakan V.; Grol,

Cor J. Department of Medicinal Chemistry, Center for CORPORATE SOURCE:

Pharmacy, State University of Groningen, Groningen,

Journal of Medicinal Chemistry (2004), 47(22),

5451-5466 CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

A series of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides was synthesized and evaluated for their interactions with

the constitutively active 5-HT7 receptor. Effects on basal adenylate cyclase activity were measured using HEK-293 cells expressing the rat 5-HT7. All ligands produced a decrease of adenylate cyclase activity, indicative of their inverse agonism. Addnl., computational studies with

set of 22 inverse agonists, including these novel inverse agonists and inverse agonists known from literature, resulted in a pharmacophore model and a CoMFA model (R2 = 0.97, SE = 0.18). Docking of inverse agonists at the binding site of a model of the helical parts of the 5-HT7 receptor, based on the α carbon template for 7-TM GPCRs, revealed interesting mol. interactions and a possible explanation for observed

structure-activity relationships.

THERE ARE 48 CITED REFERENCES AVAILABLE FOR REFERENCE COUNT: THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

SOURCE:

RX (26) OF 111 ...AY + BA ===>

L2 ANSWER 5 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

> STAGE (2) RCT BO 108-00-9 SOL 75-09-2 CH2Cl2 CON 16 hours, room temperature

PRO CB 627093-92-9

ANSWER 6 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

(Continued)

YIELD 86%

RX (26) RCT AY 1019-45-0, BA 553-90-2

RGT BC 865-47-4 t-BuOK

PRO BB 103858-17-9

SOL 68-12-2 DMF CON 4 hours, reflux

ACCESSION NUMBER: TITLE:

L2 ANSWER 7 OF 31 CASREACT COPYRIGHT 2007 ACS on STN 141:38763 CASREACT

A New Strategy toward Indole Alkaloids Involving an Intramolecular Cycloaddition/Rearrangement Cascade Padwa, Albert; Brodney, Michael A.; Lynch, Stephen

AUTHOR (S): M.;

Rashatasakhon, Paitoon; Wang, Qiu; Zhang, Hongjun CORPORATE SOURCE: Department of Chemistry, Emory University, Atlanta, GA, 30322, USA

SOURCE:

Journal of Organic Chemistry (2004), 69(11), 3735-3745

PUBLISHER:

CODEN: JOCEAH; ISSN: 0022-3263 American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

II

The intramol. Diels-Alder reaction between an amidofuran moiety tethered onto an indole component was examined as a strategy for the synthesis of Aspidosperma alkaloids. Furanyl carbamate I was acylated using a mixed anhydride of indole acetic acid to provide amidofuran II (R = H) in 68% yield. Further N-acylation of this indole furnished II (R = C(O)Me) in 88% yield. Cyclization precursors were prepared by removing the

carbamate moiety followed by N-alkylation with the appropriate alkyl halides.

substituent groups on the amido nitrogen atom causes the reactive s-trans conformation of the amidofuran to be more highly populated, thereby

ANSWER 7 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) RGT N 32503-27-8 Bu4N.HSO4, O 1310-73-2 NaOH

SOL 75-09-2 CH2C12

5 minutes, room temperature CON

STAGE (2)

RCT L 75-36-5

RGT F 7732-18-5 Water

PRO M 212561-13-2

ANSWER 7 OF 31 CASREACT COPYRIGHT 2007 ACS on STN facilitating the Diels-Alder cycloaddn. The reaction requires the presence of an electron-withdrawing substituent on the indole nitrogen in order for the cycloaddn, to proceed. Treatment of N-allyl-bromoenamide III (R1 = allyl, R2 = Br) with n-Bu3SnH/AIBN preferentially led to the 6-endo trig cyclization product III (R1, R2 = (CH2)3), with the best

(91%) being obtained under high diln. conditions. The initially

generated cyclohexenyl radical derived from III (R1 = allyl, R2 = Br) produces the pentacyclic heterocycle III (R1, R2 = (CH2)3) by either a direct 6-endo trig cyclization or, alternatively, by a vinyl radical rearrangement

pathway. REFERENCE COUNT: THERE ARE 97 CITED REFERENCES AVAILABLE FOR THIS

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

RX(3) OF 206

YIELD 90%

RX(3) RCT H 212561-12-1 STAGE(1)

L2 ANSWER B OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 140:287242 CASREACT

3-(2-Pyrrolidin-1-ylethyl)-5-(1,2,3,6-TITLE: tetrahydropyridin-4-yl)-1H-indole derivatives as high

affinity human 5-HTlb/1D ligands

Egle, Ian; MacLean, Neil; Demchyshyn, Lidia; Edward, AUTHOR (S):

Louise; Slassi, Abdelmalik; Tehim, Ashok NPS Pharmaceuticals Inc, Mississauga, ON,

Bioorganic & Medicinal Chemistry Letters (2004), SOURCE:

14(3), 727-729

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

AB A series of

3-(2-pyrrolidin-1-ylethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivs. has been prepared using parallel synthesis techniques,

their structure-activity relationships studied. High affinity human

5-HT1b/1D (h5-HT1b/1D) ligands have been identified. 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR REFERENCE COUNT:

THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE **FORMAT**

RX(3) OF 129 ...G + J ===> K...

RX(3) RCT G 17274-68-9, J 18162-48-6

(Continued)

```
ANSWER 8 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                         (Continued)
                                                                                        ANSWER B OF 31 CASREACT COPYRIGHT 2007 ACS on STN
         RGT L 1070-89-9 (Me3Si) 2N.Na
         PRO K 255711-67-2
         SOL 68-12-2 DMF
                                                                                             RCT G 17274-68-9, J 18162-48-6
       CON 0 deg C
                                                                                             RGT L 1070-89-9 (Me3Si)2N.Na
                                                                                                 K 255711-67-2
                                                                                             SOL 68-12-2 DMF
RX(27) OF 129 COMPOSED OF RX(3), RX(4)
                                                                                             CON 0 deg C
        G + J + M ===> N
RX(27)
                                                                                             RCT K 255711-67-2
                                                                                    RX (4)
                                                                                               STAGE(1)
                                                                                                  RGT O 594-19-4 t-BuLi
                                                                                                  SOL 109-99-9 THF, 109-66-0 Pentane
                                                                                                  CON 1 hour, -78 deg C
                                                                                               STAGE (2)
                                                                                                  RCT M 79099-07-3
                                                                                                  SOL 109-99-9 THF
                                                                                                  CON SUBSTAGE(1) -78 deg C -> room temperature
                                                                                                       SUBSTAGE(2) 2 hours, room temperature
                                                                                               STAGE (3)
                                                                                                  RGT P 12408-02-5 H+
                                                                                                  CON pH 7
                                                                                              PRO N 675841-44-8
              OBu-t
                                                                                                                    bud dute)
                       2
```

YIELD 48%

ANSWER 9 OF 31 CASREACT COPYRIGHT 2007 ACS on STN ANSWER 9 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) 138:205240 CASREACT ACCESSION NUMBER: TITLE: Synthesis of a psilocin hapten and a protein-hapten RZ = 5ub. alky1 Albers, Christian; Lehr, Matthias; Beike, Justus; AUTHOR (S): Kohler, Helga; Brinkmann, Bernd CORPORATE SOURCE: Institute of Pharmaceutical and Medicinal Chemistry University of Munster, Munster, D-48149, Germany Journal of Pharmacy and Pharmacology (2002), 54(9), SOURCE: 1265-1270 CODEN: JPPMAB; ISSN: 0022-3573 PUBLISHER: Pharmaceutical Press DOCUMENT TYPE: Journal YIELD 74% LANGUAGE: English AB Derivs. of psilocin with ω -functionalized alkyl spacers in position 1 of the indole ring were synthesized as haptens for use in a RIA. Whereas the psilocin analogs with a 3-aminopropyl and a 4-aminobutyl RX(1) RCT A 28383-23-5 moiety at the indole nitrogen decomposed during synthesis, the analogous 3-carboxypropyl psilocin derivative proved to be stable. This compound STAGE(1) RGT D 7646-69-7 NaH coupled to bovine serum albumin (BSA) using the N-hydroxysuccinimide SOL 68-12-2 DMF ester-mediated conjugation. The protein-hapten conjugate was CON SUBSTAGE(1) 30 minutes, 0 deg C characterized by matrix-assisted laser desorption ionization mass SUBSTAGE(2) 30 minutes, 0 deg C spectrometry. The mass spectrometry data indicated an average STAGE (2) incorporation RCT B 98346-35-1 ratio of 4-5 mols. of psilocin hapten per mol. of BSA. 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR SOL 68-12-2 DMF REFERENCE COUNT: THIS CON SUBSTAGE(1) 30 minutes, 0 deg C RECORD. ALL CITATIONS AVAILABLE IN THE RE SUBSTAGE(2) 4 hours, 60 deg C FORMAT SUBSTAGE(3) overnight, room temperature PRO C 500003-01-0 RX(1) OF 9 RX(5) OF 9 + R ==> F... R1= sub alkory

(Continued)

L2 ANSWER 9 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

```
Ph NMe2
```

F YIELD 49%

RX(5) RCT A 28383-23-5

STAGE(1) RGT D 7646-69-7 NaH SOL 68-12-2 DMF

CON SUBSTAGE(1) 30 minutes, 0 deg C SUBSTAGE(2) 30 minutes, 0 deg C

STAGE(2) RCT R

RCT R 5332-06-9
SOL 68-12-2 DMF
CON SUBSTAGE(1) 30 minutes, 0 deg C
. SUBSTAGE(2) overnight, room temperature

PRO F 500003-02-1

RX(7) OF 9 COMPOSED OF RX(5), RX(2) RX(7) A + R ===> G

Ph NMe2

$$CH_2$$
 3 $C = N$
 CH_2 4 CH_2 5 CH_2 6 CH_2 8 CH_2 8 CH_2 9 C

L2 ANSWER 9 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

AIETD 86#

RX(5) RCT A 28383-23-5

STAGE (1)

RGT D 7646-69-7 NaH SOL 68-12-2 DMF

CON SUBSTAGE(1) 30 minutes, 0 deg C SUBSTAGE(2) 30 minutes, 0 deg C

SUBSTAGE(2) 30 minutes, 0 deg

STAGE (2)

RCT R 5332-06-9 SOL 68-12-2 DMF

CON SUBSTAGE(1) 30 minutes, 0 deg C SUBSTAGE(2) overnight, room temperature

PRO F 500003-02-1

RX(2) RCT F 500003-02-1 RGT H 1333-74-0 H2

PRO G 500003-03-2

CAT 7440-02-0 Ni SOL 67-56-1 MeOH

CON 38 hours, room temperature

NTE Raney nickel used

RX(8) OF 9 COMPOSED OF RX(5), RX(3)RX(8) A + R ===> K

```
L2 ANSWER 9 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)
```

K YIELD 36%

RX(5) RCT A 28383-23-5

STAGE(1)

RGT D 7646-69-7 NaH SOL 68-12-2 DMF

CON SUBSTAGE(1) 30 minutes, 0 deg C SUBSTAGE(2) 30 minutes, 0 deg C

STAGE(2)

RCT R 5332-06-9 SOL 68-12-2 DMF

CON SUBSTAGE(1) 30 minutes, 0 deg C SUBSTAGE(2) overnight, room temperature

PRO F 500003-02-1

RX(3) RCT F 500003-02-1

STAGE(1)

RGT L 1310-58-3 KOH SOL 64-17-5 EtOH, 7732-18-5 Water

CON 10 hours, reflux

STAGE (2)

RGT M 764

RGT M 7647-01-0 HCl SOL 7732-18-5 Water

PRO K 500003-04-3

L2 ANSWER 9 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

RX(9) OF 9 COMPOSED OF RX(5), RX(3), RX(4)RX(9) A + R ===> P

P YIELD 95%

RX(5) RCT A 28383-23-5

STAGE(1)

FGT D 7646-69-7 NAH SOL 68-12-2 DMF

CON SUBSTAGE(1) 30 minutes, 0 deg C SUBSTAGE(2) 30 minutes, 0 deg C

STAGE(2)

RCT R 5332-06-9 SOL 68-12-2 DMF

CON SUBSTAGE(1) 30 minutes, 0 deg C SUBSTAGE(2) overnight, room temperature

PRO F 500003-02-1

RX(3) RCT F 500003-02-1

STAGE (1)

RGT L 1310-58-3 KOH SOL 64-17-5 EtOH, 7732-18-5 Water

CON 10 hours, reflux

STAGE(2)

Searched by Jason M. Nolan, Ph.D.

ANSWER 9 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) RGT M 7647-01-0 HC1 SOL 7732-18-5 Water PRO K 500003-04-3

RX (4) RCT K 500003-04-3

RGT H 1333-74-0 H2 PRO P 500003-05-4

CAT 7440-05-3 Pd SOL 64-17-5 EtOH, 7732-18-5 Water

CON 2 hours, room temperature

ANSWER 10 OF 31 CASREACT COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 138:137448 CASREACT

TITLE:

Intramolecular Amidofuran Cycloadditions across an Indole π -Bond: An Efficient Approach to the

Aspidosperma and Strychnos ABCE Core

Lynch, Stephen M.; Bur, Scott K.; Padwa, Albert AUTHOR (S): Department of Chemistry, Emory University, Atlanta, CORPORATE SOURCE:

GA, 30322, USA Organic Letters (2002), 4(26), 4643-4645

SOURCE: CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

Journal

DOCUMENT TYPE: LANGUAGE: English

The intramol. Diels-Alder reaction between an amidofuran moiety tethered onto an indole component was examined as a strategy for the synthesis of Aspidosperma and Strychnos alkaloids. Furanyl carbamate was acylated using a mixed anhydride to provide amidofuran I (R = H, R1 = CO2CMe3) in 68% yield. Further N-acylation of this indole furnished I (R = COMe, R1

CO2CMe3) in 88% yield. Cyclization precursors were prepared by removing carbamate moiety followed by N-alkylation with the appropriate alkyl halides. Thermolysis of II provided the novel tetracyclic ketone III in

74% yield. REFERENCE COUNT: THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS

FORMAT

SOURCE:

ANSWER 10 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

RX(2) OF 59 ...C + H ===> I...

I YIELD 90%

RX (2) RCT C 212561-12-1

> STAGE(1) RGT J 32503-27-8 Bu4N.HS04, K 1310-73-2 NaOH

SOL 75-09-2 CH2C12 CON 5 minutes, room temperature

STAGE (2)

RCT H 75-36-5

CON 1 hour, room temperature

STAGE (3)

RGT E' 7732-18-5 Water CON room temperature

PRO I 212561-13-2

L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN 136:263284 CASREACT

ACCESSION NUMBER:

TITLE:

The chemistry of indoles. Part 109. Synthetic studies of psilocin analogs having either a formyl group or bromine atom at the 5- or 7-position

RECORD. ALL CITATIONS AVAILABLE IN THE RE

RECORD. ALL CITATIONS AVAILABLE IN THE RE

Yamada, Fumio; Tamura, Mayumi; Hasegawa, Atsuko; AUTHOR (S):

Somei, Masanori

Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, 920-0934, Japan

Chemical & Pharmaceutical Bulletin (2002), 50(1), 92-99

CODEN: CPBTAL; ISSN: 0009-2363

Pharmaceutical Society of Japan PUBLISHER: Journal

DOCUMENT TYPE: LANGUAGE: English

Psilocin (I) analogs having either a formyl group or a bromine atom at

5- or 7-position have been prepared for the first time. Syntheses of 5-

and 7-bromo derivs. of 4-hydroxy- and 4-benzyloxyindole-3-carbaldehyde, 4-benzyloxyindole-3-acetonitriles, and 4-benzyloxy-N, N-dimethyltryptamine have also been established.

THERE ARE 20 CITED REFERENCES AVAILABLE FOR REFERENCE COUNT: THIS

FORMAT

RX(3) OF 114

L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

OHC NMe₂

J YIELD 78%

RX(3) RCT C 404887-81-6, I 24424-99-5 RGT K 1122-58-3 4-DMAP PRO J 404887-84-9

SOL 75-09-2 CH2C12

RX(4) OF 114 ...D + I ===> M

CHO H
NMe2

$$t-BuO$$
OBu-t

I

L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

M YIELD 66%

RX(4) RCT D 404887-83-8, I 24424-99-5 RGT K 1122-58-3 4-DMAP PRO M 404887-85-0 SOL 75-09-2 CH2C12

RX(22) OF 114 ...BC + I ===> BH

L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

t-BuO O NMe2

BH YIELD 83%

RX(22) RCT BC 404888-06-8, I 24424-99-5 RGT K 1122-58-3 4-DMAP PRO BH 404888-08-0 SOL 75-09-2 CH2C12

RX(24) OF 114 BB + I ===> BL...

Ph O

BL YIELD 96% L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

RX(24) RCT BB 28383-23-5, I 24424-99-5 RGT K 1122-58-3 4-DMAP PRO BL 404888-10-4

SOL 75-09-2 CH2C12

RX(31) OF 114 COMPOSED OF RX(1), RX(3) RX(31) 2 A + 2 B + I ===> J

H NMe2

NMe2

A

CH3
N * O OBu-t 2
2 B I STEPS

OHC NMe2

RX(1)

STAGE(1) RGT E 10025-87-3 POC13 SOL 68-12-2 DMF

RCT A 520-53-6, B 68-12-2

L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

STAGE(2) RGT F 1310-73-2 NaOH SOL 7732-18-5 Water

STAGE (3)

RGT G 7647-01-0 HCl SOL 7732-18-5 Water

PRO C 404887-81-6, D 404887-83-8

NTE yield depends on reaction conditions

RX(3) RCT C 404887-81-6, I 24424-99-5 RGT K 1122-58-3 4-DMAP

PRO J 404887-84-9 SOL 75-09-2 CH2C12

RX(32) OF 114 COMPOSED OF RX(1), RX(4) RX(32) 2 A + 2 B + I ===> M

L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

M YIELD 66%

RX(1) RCT A 520-53-6, B 68-12-2

STAGE(1)

RGT E 10025-87-3 POC13 SOL 68-12-2 DMF

STAGE (2)

RGT F 1310-73-2 NaOH SOL 7732-18-5 Water

STAGE (3)

RGT G 7647-01-0 HCl SOL 7732-18-5 Water

PRO C 404887-81-6, D 404887-83-8 NTE yield depends on reaction conditions

RX(4) RCT D 404887-83-8, I 24424-99-5

RGT K 1122-58-3 4-DMAP PRO M 404887-85-0

SOL 75-09-2 CH2C12

RX(47) OF 114 COMPOSED OF RX(20), RX(22) RX(47) BB + I ===> BH

L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

BH YIELD 83%

RX(20) RCT BB 28383-23-5 RGT W 110-86-1 Pyridine, X 10035-10-6 HBr, Y 7726-95-6 Br2 PRO BC 404888-06-8

SOL 67-66-3 CHC13, 60-29-7 Et20

RX(22) RCT BC 404888-06-8, I 24424-99-5

RGT K 1122-58-3 4-DMAP PRO BH 404888-08-0

SOL 75-09-2 CH2C12

RX(52) OF 114 COMPOSED OF RX(24), RX(25) RX(52) BB + I ==> BM

L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

BM YIELD 93%

RX(24) RCT BB 28383-23-5, I 24424-99-5 RGT K 1122-58-3 4-DMAP PRO BL 404888-10-4

RX(25) RCT BL 404888-10-4 RGT AK 1333-74-0 H2 PRO BM 404888-11-5 CAT 7440-05-3 Pd

SOL 67-56-1 MeOH

RX(81) OF 114 COMPOSED OF RX(24), RX(25), RX(26) RX(81) BB + I ===> BI

ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

YIELD 87%

RX (24) RCT BB 28383-23-5, I 24424-99-5 RGT K 1122-58-3 4-DMAP

PRO BL 404888-10-4 SOL 75-09-2 CH2C12

RCT BL 404888-10-4 RX (25) RGT AK 1333-74-0 H2 PRO BM 404888-11-5 .

CAT 7440-05-3 Pd SOL 67-56-1 MeOH

RX (26) RCT BM 404888-11-5 RGT W 110-86-1 Pyridine, X 10035-10-6 HBr, Y 7726-95-6 Br2 PRO BI 404888-12-6 SOL 67-66-3 CHC13, 60-29-7 Et20

RX(84) OF 114 COMPOSED OF RX(24), RX(25), RX(26), RX(23) RX(84) BB + I + AR ==> BJ

L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) RX(23) RCT BI 404888-12-6

RGT BK 7693-26-7 KH SOL 68-12-2 DMF

STAGE (2) RCT AR 100-39-0 SOL 68-12-2 DMF

STAGE (3) SOL 7732-18-5 Water

PRO BJ 404888-09-1

L2 ANSWER 11 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

STEPS

YIELD 43%

RCT BB 28383-23-5, I 24424-99-5 RX (24) RGT K 1122-58-3 4-DMAP

PRO BL 404888-10-4 SOL 75-09-2 CH2C12

RX (25) RCT BL 404888-10-4 RGT AK 1333-74-0 H2 PRO BM 404888-11-5

CAT 7440-05-3 Pd SOL 67-56-1 MeOH

RX (26) RCT BM 404888-11-5 RGT W 110-86-1 Pyridine, X 10035-10-6 HBr, Y 7726-95-6 Br2

PRO BI 404888-12-6 SOL 67-66-3 CHC13, 60-29-7 Et20

L2 ANSWER 12 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 135:371593 CASREACT

TITLE: New bis-indolic macrolactams Henin, Jacques: Noe, Eric: Laronze, Jean-Yves AUTHOR (S):

CORPORATE SOURCE: Laboratoire de Chimie Therapeutique, UMR-CNRS 6013,

IFR no 53 Biomolecules, UFR de Pharmacie, Reims, 51096, Fr.

Synthesis (2001), (11), 1693-1703 SOURCE:

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Treatment of several m-halogenoamides, e.g. I, derived from tryptamine, with powdered potassium hydroxide in 1,2-dimethoxyethane in

presence of 18-crown-6, resulted in intramol. and/or bimol. cyclization, depending on the length of the chain and dilution conditions, to give macrocyclic compds, e.g. II and III. Some of them were converted by a

Bischler-Napieralski reaction, followed by sodium borohydride reduction,

new tetracyclic derivs. of β -carbolines, e.g. IV. 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR

THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RX(6) OF 36 ...3 G ===> 0 + P

L2 ANSWER 12 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

O YIELD 36%

L2 ANSWER 12 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

YIELD 7%

RX (6) RCT G 374558-11-9 RGT J 1310-58-3 KOH, K 17455-13-9 18-Crown-6 PRO O 292029-81-3, P 374558-17-5 SOL 110-71-4 (CH2OMe)2 NTE in the dark

The chemistry of indoles. CIII. Simple syntheses of TITLE: serotonin, N-methylserotonin, bufotenine, 5-methoxy-N-methyltryptamine, bufobutanoic acid, and

134:222891 CASREACT

L2 ANSWER 13 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

N-(indol-3-yl)methyl-5-methoxy-N-methyltryptamine, lespedamine based on 1-hydroxyindole chemistry

AUTHOR (S):

SOURCE:

Somei, Masanori; Yamada, Fumio; Kurauchi, Takashi; Nagahama, Yoshiyuki; Hasegawa, Masakazu; Yamada, Koji; Teranishi, Sakiko; Sato, Haruhiko; Kaneko, Chikara

CORPORATE SOURCE:

ACCESSION NUMBER:

Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, 920-0934, Japan Chemical & Pharmaceutical Bulletin (2001), 49(1), CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English AB Application of regioselective nucleophilic substitution reactions of 1-hydroxytryptamines to novel and simple syntheses of serotonin, N-methylserotonin, bufotenine, 5-methoxy-N-methyltryptamine, bufobutanoic acid, N-(indol-3-yl)methyl-5-methoxy-N-methyltryptamine, and lespedamine are described. Effective syntheses of 5-benzyloxytryptamine and

1-methoxy-2-oxindoles are also reported. 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR REFERENCE COUNT:

THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

RX(32) OF 146

BX BY

NMe2

YIELD 50%

RX (32) RCT BX 1019-45-0 ANSWER 13 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) STAGE (1) RGT BM 7646-69-7 NaH SOL 68-12-2 DMF STAGE (2)

SOL 68-12-2 DMF

STAGE (3) RGT U 1310-73-2 NaOH

SOL 67-66-3 CHC13, 67-56-1 MeOH

PRO BZ 39998-63-5

RX(33) OF 146

(33) BX ΑI

CA YIELD 32%

RCT BX 1019-45-0, AI 64-18-6 RX (33) PRO CA 329763-96-4 SOL 64-18-6 HCO2H

L2 ANSWER 14 OF 31 CASREACT COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 131:102170 CASREACT

TITLE:

Radical promoted cyclizations of trichloroacetamides with silyl enol ethers and enol acetates: the role of the hydride reagent (tris(trimethylsily1)silane vs.

tributy1stannane] AUTHOR (S):

Quirante, Josefina; Escolano, Carmen; Diaba, Faiza;

Bonjoch, Josep CORPORATE SOURCE:

Faculty of Pharmacy, Laboratory of Organic Chemistry, University of Barcelona, Barcelona, 08028, Spain Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1999), (9),

1157-1162 -

CODEN: JCPRB4; ISSN: 0300-922X Royal Society of Chemistry

PUBLISHER: DOCUMENT TYPE: Journal LANGUAGE:

English AB Reactions between 1-(carbamoyl)dichloromethyl radicals and electron-rich alkenes acting as radical acceptors are reported for the first time. The intramol. reaction of trichloroacetamides with silyl enol ethers gives ketones using (TMS)3SiH as the mediator, alcs. when using Bu3SnH. The reaction with enol acetates gives acetates using either of the above hydride reagents. These radical processes have been applied to the

synthesis of 2-azabicyclo[3.3.1] nonanes. 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS

FORMAT

SOURCE:

RECORD. ALL CITATIONS AVAILABLE IN THE RE

RX(12) OF 20 ...2 AA ===> AC

AA

L2 ANSWER 14 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

YIELD 60%

AA

RX (12) RCT AA 230951-61-8

> STAGE(1) RGT N 78-67-1 AIBN SOL 71-43-2 Benzene

STAGE (2) RGT O 1873-77-4 (Me3Si) 3SiH

PRO AC 230951-62-9

RX(20) OF 20 COMPOSED OF RX(10), RX(12) RX(20) 2 Y + 2 I ===> AC

ANSWER 14 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

STEPS

AC YIELD 60%

RCT Y 171367-15-0, I 108-22-5 RX (10)

> RGT K 104-15-4 TsOH SOL 108-22-5 H2C:CMeOAc

ANSWER 14 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) STAGE (2) RGT E 144-55-8 NaHCO3 SOL 7732-18-5 Water

PRO AA 230951-61-8

STAGE (1) RGT N 78-67-1 AIBN SOL 71-43-2 Benzene

STAGE (2) RGT O 1873-77-4 (Me3Si) 3SiH

PRO AC 230951-62-9

L2 ANSWER 15 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

113:171965 CASREACT ACCESSION NUMBER: TITLE:

First electrophilic substitution of (-)-agroclavine, indoramine, phenothiazine, chlorpromazine,

iminodibenzyl, imipramine, and phenazone with

triethyl

orthoformate as an al-synthon

AUTHOR (S): Pindur, Ulf: Witzel, Helmut CORPORATE SOURCE:

Inst. Pharm., Univ. Mainz, Mainz, D-6500/1, Germany SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1990),

323(7), 439-42

CODEN: ARPMAS; ISSN: 0365-6233

Journal DOCUMENT TYPE: LANGUAGE: English

Agroclavine, imipramine, hydrochloride, and phenazone reacted with tri-Et orthoformate under acid catalysis in an electrophilic, tandem

reaction to furnish C3-sym. tris(heteroaryl)methanes while indoramine, phenothiazine, and iminodibenzyl were formylated, ethylated, or ethoxymethylated.. The ambident electrophilic reactivity of tri-Et orthoformate as an al-synthon was clearly apparent.

RX (7) OF 7 T + B ==> U

T

L2 ANSWER 16 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 112:98939 CASREACT TITLE:

Intramolecular cyclization of (methylthio) furopyridones

Naito, Takeaki; Miyata, Okiko; Ninomiya, Ichiya Kobe Women's Coll. Pharm., Kobe, 658, Japan AUTHOR (S): CORPORATE SOURCE:

SOURCE: Heterocycles (1989), 29(3), 459-62

CODEN: HTCYAM; ISSN: 0385-5414 DOCUMENT TYPE: Journal

LANGUAGE:

English

Methylthiofuropyridone I is potential synthon for the construction of indoloquinolizidine derivs., e.g. II, by the intramol. cyclization involving methylthio and lactam carbonyl groups.

RX(4) OF 50

2 G

L2 ANSWER 15 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

YIELD 44%

RCT T 38821-52-2, B 122-51-0 RX (7)


RGT D 76-03-9 C13CCO2H PRO U 129961-35-9

SOL 122-51-0 CH(OEt)3

NTE 40% E-rotamer, 60% Z-rotamer

L2 ANSWER 16 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

(Continued)



J YIELD 24%

K YIELD 24%

L YIELD 21%

RX (4) RCT G 125218-02-2 RGT M 584-08-7 K2CO3, N 74-88-4 MeI PRO J 125218-06-6, K 125279-28-9, L 125218-03-3

RX(14) OF 50 COMPOSED OF RX(3), RX(4) RX(14) 4 F ==> J + K + L

L2 ANSWER 16 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

H N O CH2

2 F

H N O CH2 2
STEPS

J YIELD 24% L2 ANSWER 16 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

Me i N N N SMe

L YIELD 21%

RX(3) RCT F 125218-01-1 RGT I 16940-66-2 NaBH4 PRO G 125218-02-2, H 125279-27-8 NTE photochem.

RX(4) RCT G 125218-02-2 RGT M 584-08-7 K2CO3, N 74-88-4 MeI PRO J 125218-06-6, K 125279-28-9, L 125218-03-3

L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 112:98416 CASREACT
TITLE: Stereoregulation of the C(12b)H-C(2)H relationship in the preparation of 2-substituted 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizines

ctahydroindolo[2,3-a]quinolizines
Lounasmaa, Mauri; Jokela, Reija
Lab. Org. Bioorg. Chem., Tech. Univ. Helsinki, Espoo,
SF-02150, Finland

SOURCE: Tetrahedron (1989), 45(12), 3975-92 CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE:

LANGUAGE: GI

AUTHOR (S):

CORPORATE SOURCE:

Journal English

NH H

AB Stereochem. control in the preparation of 2-substituted 1,2,3,4,6,7,12,12b- octahydroindolo[2,3-a]quinolizines I (R = H, Me, CMe3), possessing at

the C(12b)H-C(2)H cis- or trans-configuration was achieved by catalytic reduction of the 2,3-dehydro analogs, which were either unsubstituted on

indole nitrogen or substituted with Me3CCO group, resp. The contribution of different conformations to the conformational equilibrium of the prepared compds. was estimated by 13C NMR spectral anal.

RX(29) OF 137 ...AQ + Z ===> AT...

2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

YIELD 90%

RX(29) RCT AQ 26628-87-5

STAGE(1)

RGT AB 1310-73-2 NaOH

CAT 32503-27-8 Bu4N.HSO4

SOL 108-88-3 PhMe, 7732-18-5 Water

STAGE(2)

RCT Z 24424-99-5 SOL 108-88-3 PhMe

PRO AT 125260-53-9

RX(30) OF 137 ...AR + Z ===> AU...

L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

t-BuO O

AU YIELD 85%

· RX(30) RCT AR 125260-52-8

STAGE(1)

RGT AB 1310-73-2 NaOH

CAT 32503-27-8 Bu4N.HSO4

SOL 108-88-3 PhMe, 7732-18-5 Water

STAGE(2)

RCT Z 24424-99-5

PRO AU 125260-54-0

SOL 108-88-3 PhMe

RX(31) OF 137 ...AS + Z ==> AV...

L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

AT YIELD 90%

RX(26) RCT G 50676-26-1 RGT V 1333-74-0 H2 PRO AQ 26628-87-5 CAT 1314-15-4 PtO2

RX(29) RCT AQ 26628-87-5

STAGE(1)

RGT AB 1310-73-2 NaOH

CAT 32503-27-8 Bu4N.HSO4

SOL 108-88-3 PhMe, 7732-18-5 Water

STAGE(2)

RCT Z 24424-99-5

SOL 108-88-3 PhMe

PRO AT 125260-53-9

RX(63) OF 137 COMPOSED OF RX(27), RX(30) RX(63) C + 2 \Rightarrow AU

L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

AV YIELD 85%

RX(31) RCT AS 58534-26-2

STAGE(1)

RGT AB 1310-73-2 NaOH

CAT 32503-27-8 Bu4N.HSO4

SOL 108-88-3 PhMe, 7732-18-5 Water

STAGE(2)

RCT Z 24424-99-5

SOL 108-88-3 PhMe

RX(62) OF 137 COMPOSED OF RX(26), RX(29) RX(62) G + Z ===> AT

PRO AV 125260-55-1

L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

AU YIELD 85%

RX(27) RCT C 24716-26-5
RGT V 1333-74-0 H2
PRO AR 125260-52-8
CAT 1314-15-4 PtO2

RX(30) RCT AR 125260-52-8

STAGE(1)
RGT AB 1310-73-2 NaOH
CAT 32503-27-8 Bu4N.HSO4
SOL 108-88-3 PhMe, 7732-18-5 Water

STAGE(2)
RCT Z 24424-99-5
SOL 108-88-3 PhMe

PRO AU 125260-54-0

RX(64) OF 137 COMPOSED OF RX(28), RX(31) RX(64) E + Z ===> AV

```
L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                              (Continued)
              • Br
             t-BuO
STEPS
           YIELD 85%
          RCT E 125285-65-6
RX (28)
          RGT V 1333-74-0 H2
          PRO AS 58534-26-2
          CAT 1314-15-4 PtO2
          RCT AS 58534-26-2
RX (31)
            STAGE(1)
               RGT AB 1310-73-2 NaOH
               CAT 32503-27-8 Bu4N.HS04
               SOL 108-88-3 PhMe, 7732-18-5 Water
            STAGE (2)
               RCT 2 24424-99-5
               SOL 108-88-3 PhMe
L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                              (Continued)
            STAGE (1)
               RGT AX 7722-84-1 H202
               RGT AY 407-25-0 (CF3CO) 20
            STAGE (3)
               RGT I 151-50-8 KCN
          PRO AW 125260-56-2
RX(66) OF 137 COMPOSED OF RX(30), RX(33)
        AR + Z ===> AZ
RX (66)
AR
             t-BuO
 2
STEPS
           AZ
YIELD 56%
RX (30)
          RCT AR 125260-52-8
            STAGE (1)
               RGT AB 1310-73-2 NaOH
CAT 32503-27-8 Bu4N.HSO4
               SOL 108-88-3 PhMe, 7732-18-5 Water
            STAGE (2)
               RCT Z 24424-99-5
```

SOL 108-88-3 PhMe

```
L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                            (Continued)
          PRO AV 125260-55-1
RX(65) OF 137 COMPOSED OF RX(29), RX(32)
RX (65)
      AQ + 2 ==> AW
ΑQ
 t-BuO
AW
YIELD 55%
RX (29)
         RCT AQ 26628-87-5
           STAGE(1)
              RGT AB 1310-73-2 NaOH
               CAT 32503-27-8 Bu4N.HS04
              SOL 108-88-3 PhMe, 7732-18-5 Water
           STAGE (2)
              RCT Z 24424-99-5
              SOL 108-88-3 PhMe
          PRO AT 125260-53-9
         RCT AT 125260-53-9
RX (32)
   ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                            (Continued)
          PRO AU 125260-54-0
RX (33)
         RCT AU 125260-54-0
           STAGE (1)
              RGT AX 7722-84-1 H202
           STAGE (2)
              RGT AY 407-25-0 (CF3CO) 20
           STAGE (3)
              RGT I 151-50-8 KCN
          PRO AZ 125260-57-3
RX(67) OF 137 COMPOSED OF RX(31), RX(34)
RX(67) AS + Z ===> AO
AS
STEPS
 t-BuO
AO
YIELD 62%
```

RX (31)

RCT AS 58534-26-2

```
L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                                                       L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                                                                                                                    (Continued)
                                                            (Continued)
           STAGE(1)
                                                                                         t-BuO
              RGT AB 1310-73-2 NaOH
              CAT 32503-27-8 Bu4N.HS04
              SOL 108-88-3 PhMe, 7732-18-5 Water
           STAGE (2)
              RCT Z 24424-99-5
              SOL 108-88-3 PhMe
         PRO AV 125260-55-1
         RCT AV 125260-55-1
RX (34)
           STAGE (1)
              RGT AX 7722-84-1 H202
                                                                                       YIELD 55%
           STAGE (2)
              RGT AY 407-25-0 (CF3CO) 20
                                                                                       RX (26)
                                                                                                 RCT G 50676-26-1
              RGT I 151-50-8 KCN
                                                                                                 RGT V 1333-74-0 H2
                                                                                                 PRO AQ 26628-87-5
                                                                                                 CAT 1314-15-4 PtO2
         PRO AO 125260-58-4
                                                                                                 RCT AQ 26628-87-5
                                                                                       RX (29)
RX(107) OF 137 COMPOSED OF RX(26), RX(29), RX(32)
RX (107) G + Z ===> AW
                                                                                                   STAGE(1)
                                                                                                      RGT AB 1310-73-2 NaOH
                                                                                                      CAT 32503-27-8 Bu4N.HS04
                                                                                                      SOL 108-88-3 PhMe, 7732-18-5 Water
                                                                                                   STAGE(2)
                                                                                                      RCT Z 24424-99-5
                                                                                                      SOL 108-88-3 PhMe
                                                                                                 PRO AT 125260-53-9
                                                                                       RX (32)
                                                                                                 RCT AT 125260-53-9
                                                                                                   STAGE (1)
                                                                                                      RGT AX 7722-84-1 H202
                                                                                                   STAGE(2)
                                                                                                      RGT AY 407-25-0 (CF3CO) 20
                                                       STEPS
                                                                                                   STAGE (3)
                                                                                                      RGT I 151-50-8 KCN
                                                                                                 PRO AW 125260-56-2
                                                                                       RX(109) OF 137 COMPOSED OF RX(27), RX(30), RX(33)
                                                                                       L2 ANSWER 17 OF 31 CASREACT COPYRIGHT. 2007 ACS on STN
                                                                                                                                                     (Continued)
L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                            (Continued)
                                                                                                   STAGE(1)
                                                                                                      RGT AX 7722-84-1 H202
                                                                                                      RGT AY 407-25-0 (CF3CO)20
                                                                                                   STAGE(3)
                                                                                                      RGT I 151-50-8 KCN
                                                                                                 PRO AZ 125260-57-3
                                                                                        RX(111) OF 137 COMPOSED OF RX(28), RX(31), RX(34)
                                                                                       RX(111) E + Z ==> AO
            • Br-
C
STEPS
                                                                                                     ● Br
                                                                                         3
           YIELD 56%
                                                                                       STEPS
RX (27)
         RCT C 24716-26-5
         RGT V 1333-74-0 H2
                                                                                         t-BuQ.
          PRO AR 125260-52-8
         CAT 1314-15-4 PtO2
RX (30)
         RCT AR 125260-52-8
           STAGE (1)
              RGT AB 1310-73-2 NaOH
              CAT 32503-27-8 Bu4N.HS04
              SOL 108-88-3 PhMe, 7732-18-5 Water
           STAGE (2)
              RCT Z 24424-99-5
              SOL 108-88-3 PhMe
                                                                                       AO
YIELD 62%
          PRO AU 125260-54-0
RX (33)
          RCT AU 125260-54-0
```

```
L2 ANSWER 17 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                            (Continued)
         RCT E 125285-65-6
RX (28)
         RGT V 1333-74-0 H2
         PRO AS 58534-26-2
         CAT 1314-15-4 PtO2
         RCT AS 58534-26-2
RX(31)
           STAGE(1)
              RGT AB 1310-73-2 NaOH
              CAT 32503-27-8 Bu4N.HS04
              SOL 108-88-3 PhMe, 7732-18-5 Water
           STAGE(2)
              RCT Z 24424-99-5
              SOL 108-88-3 PhMe
         PRO AV 125260-55-1
```

RGT AX 7722-84-1 H202 STAGE(2) RGT AY 407-25-0 (CF3CO) 20

RGT I 151-50-8 KCN PRO AO 125260-58-4

L2 ANSWER 18 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 111:56746 CASREACT TITLE:

Photochemistry of the phthalimide system. XLI. Intramolecular photoreactions of phthalimide-alkene systems. Oxetane formation of N-(m-indol-3-

ylalkyl)phthalimides Takechi, Haruko; Machida, Minoru; Kanaoka, Yuichi AUTHOR (S):

Fac. Pharm. Sci., Higashi-Nippon-Gakuen Univ., CORPORATE SOURCE: Hokkaido, 061-02, Japan SOURCE:

Chemical & Pharmaceutical Bulletin (1988), 36(8), 2853-63

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

English

LANGUAGE: GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Upon irradiation in acetone, $N-(\omega-indol-3-ylalkyl)$ phthalimides I (n = 2-5) underwent intramol. Paterno-Buchi reaction to give oxeto[2,3-b]indoles (II) or their ring-opened products. However, $N-(\omega-indol-2-ylalkyl)$ phthalimides III (n = 2, 3) yielded not the oxetane, but the N-deacetylated compds. IV.

RX(17) OF 72 ...AP ===> D...

ANSWER 18 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

RX(17) RCT AP 15741-71-6 RGT AL 108-24-7 Ac20, AM 584-08-7 K2CO3 PRO D 85632-71-9 SOL 68-12-2 DMF

RX(34) OF 72 ...AP ===> N...

N YIELD 60%

L2 ANSWER 18 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

RCT AP 15741-71-6 RX (34) RGT AM 584-08-7 K2CO3, BK 407-25-0 (CF3CO)20 PRO N 85616-85-9 SOL 68-12-2 DMF

...AP ===> BL RX(35) OF 72

BL YIELD 90%

RX (35) RCT AP 15741-71-6 STAGE (1) RGT BM 7693-26-7 KH SOL 109-99-9 THF STAGE (2) RGT AI 74-88-4 MeI PRO BL 70369-20-9

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 110:95591 CASREACT TITLE: Synthesis of compound

Synthesis of compounds in the eburnamoninehomoeburnamonine series

CORPORATE SOURCE:

Jokela, Reija; Karvinen, Esko; Tolvanen, Arto; Lounasmaa, Mauri Lab. Org. Bbioorg. Chem., Tech. Univ. Helsinki,

CORPORATE SOURCE: Espoo,

AUTHOR (S):

SF-02150, Finland

SOURCE: Tetrahedron (1988), 44(8), 2367-75 CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE:

Journal English

LANGUAGE:

AB Six different lactams of the desethyleburnamonine-homoeburnamonine series,

e.g. I, were synthesized. Thus, the piperidinoethylindole II, prepared

steps from Me 3-pyridylacetate and tryptophyl bromide, was cyclized by AgBF4 to give 70% I. Complete 13C NMR data are presented for these compds., as well as for their precursors. Special attention is paid to their C(20)-C(21) stereochem.

RX(3) OF 66 ...B + G ===> H...

(3)

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

M YIELD 98%

2 STEPS

RX(4) RCT F 119100-73+1

STAGE(1) RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH SOL 7732-18-5 Water, 108-88-3 PhMe

301 //32-10-3 Water, 100-00

RCT G 24424-99-5

SOL 108-88-3 PhMe

RX(20) OF 66 COMPOSED OF RX(1), RX(3) RX(20) A + G ===> H

PRO M 119100-75-3

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

HYIELD 98%

RX(3) RCT B 50676-27-2

STAGE(1) RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH SOL 7732-18-5 Water, 108-88-3 PhMe

STAGE(2)

RCT G 24424-99-5 SOL 108-88-3 PhMe

PRO H 119100-74-2

RX(4) OF 66 ...F + G ===> M..

(4)

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

AIETD 38#

RX(1) RCT A 14996-87-3 RGT C 1333-74-0 H2 PRO B 50676-27-2 CAT 1314-15-4 PtO2

RX(3) RCT B 50676-27-2

STAGE(1) RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH SOL 7732-18-5 Water, 108-88-3 PhMe

STAGE(2) RCT G 24424-99-5 SOL 108-88-3 PhMe

PRO H 119100-74-2

RX(21) OF 66 COMPOSED OF RX(2), RX(4) RX(21) E + G ===> M

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

STEPS

T-BuO

N

H

H

OMe

M YIELD 98%

RX(2) RCT E 89486-66-8 RGT C 1333-74-0 H2 PRO F 119100-73-1 CAT 1314-15-4 PtO2

RX(4) RCT F 119100-73-1

STAGE(1) RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH SOL 7732-18-5 Water, 108-88-3 PhMe

STAGE(2) RCT G 24424+99-5 SOL 108-88-3 PhMe

PRO M 119100-75-3

RX(22) OF 66 COMPOSED OF RX(3), RX(5) RX(22) B + G ===> N

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

STEPS

OME

RX(4) RCT F 119100-73-1

YIELD 90%

STAGE(1)

RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH

SOL 7732-18-5 Water, 108-88-3 PhMe

SOL 7732-18-5 Water, 67-66-3 CHCl3, 67-56-1 MeOH

RCT G 24424-99-5 SOL 108-88-3 PhMe

RX(6) RCT M 119100-75-3 RGT O 7722-84-1 H202 PRO R 119100-83-3

PRO M 119100-75-3

RX(34) OF 66 COMPOSED OF RX(1), RX(3), RX(5) $\mathbb{R}X\{34\}$ A + G ==> N

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

2
STEPS
N
OME

RX(3) RCT B 50676-27-2

YIELD 90%

STAGE(1)

RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH
SOL 7732-18-5 Water, 108-88-3 PhMe

STAGE(2) RCT G 24424-99-5 SOL 108-88-3 PhMe

PRO H 119100-74-2

RX(5) RCT H 119100-74-2 RGT O 7722-84-1 H202 PRO N 119137-70-1 SOL 7732-18-5 Water, 67-66-3 CHC13, 67-56-1 MeOH

RX(23) OF 66 COMPOSED OF RX(4), RX(6) RX(23) F + G ===> R

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

> N YIELD 90%

RX(1) RCT A 14996-87-3 RGT C 1333-74-0 H2 PRO B 50676-27-2 CAT 1314-15-4 PtO2

RX(3) RCT B 50676-27-2

STAGE(1) RGT I 32503-27-8 Bu4N.HS04, J 1310-73-2 NaOH SOL 7732-18-5 Water, 108-88-3 PhMe

> STAGE(2) RCT G 24424-99-5 SOL 108-88-3 PhMe

PRO H 119100-74-2

RX(5) RCT H 119100-74-2 RGT O 7722-84-1 H202 PRO N 119137-70-1 SOL 7732-18-5 Water, 67-66-3 CHC13, 67-56-1 MeOH

RX(36) OF 66 COMPOSED OF RX(2), RX(4), RX(6) RX(36) E + G == \Rightarrow R L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

R YIELD 90%

RX(2) RCT E 89486-66-8 RGT C 1333-74-0 H2 PRO F 119100-73-1 CAT 1314-15-4 PtO2

RX(4) RCT F 119100-73-1

TAGE(1) RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH SOL 7732-18-5 Water, 108-88-3 PhMe

STAGE (2) RCT G 24424-99-5 SOL 108-88-3 PhMe L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) PRO M 119100-75-3

RX(6) RCT M 119100-75-3 RGT O 7722-84-1 H202 PRO R 119100-83-3 SOL 7732-18-5 Water, 67-66-3 CHC13, 67-56-1 MeOH

RX(38) OF 66 COMPOSED OF RX(3), RX(5), RX(18) RX(38) 2 B + 2 G ==> S + AW

3 STEPS

YIELD 86% (50)

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

AW YIELD 86% (50)

RX(3) RCT B 50676-27-2

STAGE(1) RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH SOL 7732-18-5 Water, 108-88-3 PhMe

STAGE (2) RCT G 24424-99-5 SOL 108-88-3 PhMe

PRO H 119100-74-2

RX(5) RCT H 119100-74-2 RGT O 7722-84-1 H202

PRO N 119137-70-1 SOL 7732-18-5 Water, 67-66-3 CHCl3, 67-56-1 MeOH


RX(18) RCT N 119137~70-1

STAGE(1) RGT BA 407-25-0 (CF3CO)20 SOL 75-09-2 CH2C12

RGT BB 151-50-8 KCN SOL 7732-18-5 Water

PRO S 119100-76-4, AW 119137-69-8

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)



S YIELD 86% (50) L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) -

NC H H H

AW YIELD 86% (50)

RX(1) RCT A 14996-87-3 RGT C 1333-74-0 H2 PRO B 50676-27-2 CAT 1314-15-4 Pto2

RX(3) RCT B 50676-27-2

STAGE(1) RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH SOL 7732-18-5 Water, 108-88-3 PhMe

STAGE(2) RCT G 24424-99-5 SOL 108-88-3 Phme

PRO H 119100-74-2

RX(5) RCT H 119100-74-2 RGT O 7722-84-1 H202

PRO N 119137-70-1 SOL 7732-18-5 Water, 67-66-3 CHC13, 67-56-1 MeOH

RX(18) RCT N 119137-70-1

TAGE(1) RGT BA 407-25-0 (CF3CO)20 SOL 75-09-2 CH2C12

STAGE(2) RGT BB 151-50-8 KCN SOL 7732-18-5 Water

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

t-BuO O CN CN CN COME

AY YIELD 91% (50)

RX(4) RCT F 119100-73-1

STAGE(1) RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH SOL 7732-18-5 Water, 108-88-3 PhMe

STAGE(2) RCT G 24424-99-5 SOL 108-88-3 PhMe

PRO M 119100-75-3

RX(6) RCT M 119100-75-3 RGT O 7722-84-1 H2O2 PRO R 119100-83-3

PRO R 119100-83-3 SOL 7732-18-5 Water, 67-66-3 CHCl3, 67-56-1 MeOH

RX(19) RCT R 119100-83-3

STAGE(1) RGT BA 407-25-0 (CF3CO)20 SOL 75-09-2 CH2C12

STAGE (2) RGT BB 151-50-8 KCN SOL 7732-18-5 Water

PRO W 119100-77-5, AY 119100-82-2

RX(41) OF 66 COMPOSED OF RX(2), RX(4), RX(6), RX(19) RX(41) 2 E + 2 G ===> W + AY

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) PRO S 119100-76-4, AW 119137-69-8

RX(40) OF 66 COMPOSED OF RX(4), RX(6), RX(19) RX(40) 2 F + 2 G ===> W + AY

STEPS

t-BuO O CN O OME

W YIELD 91% (50)

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

Br - t-BuO OBu-t

2 E 2 G

STEPS

NC

NC

H

OMe

YIELD 91% (50)

Searched by Jason M. Nolan, Ph.D.

L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) L2 ANSWER 19 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) PRO W 119100-77-5, AY 119100-82-2

AY YIELD 91% (50)

RCT E 89486-66-8 RX (2) RGT C 1333-74-0 H2 PRO F 119100-73-1 CAT 1314-15-4 PtO2

RCT F 119100-73-1 RX (4)

> STAGE(1) RGT I 32503-27-8 Bu4N.HSO4, J 1310-73-2 NaOH SOL 7732-18-5 Water, 108-88-3 PhMe

STAGE(2) RCT G 24424-99-5 SOL 108-88-3 PhMe

PRO M 119100-75-3

RCT M 119100-75-3 RX (6) RGT 0 7722-84-1 H202 PRO R 119100-83-3

SOL 7732-18-5 Water, 67-66-3 CHCl3, 67-56-1 MeOH

RCT R 119100-83-3 RX (19)

STAGE(1)

RGT BA 407-25-0 (CF3CO) 20 SOL 75-09-2 CH2C12

STAGE (2) RGT BB 151-50-8 KCN SOL 7732-18-5 Water

L2 ANSWER 20 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 109:129408 CASREACT

A mild novel synthesis of simple 1-oxo- β -TITLE: carbolines

Jokela, Reija; Lounasmaa, Mauri AUTHOR (S):

Lab. Org. Bioorg. Chem., Tech. Univ. Helsinki, Espoo, CORPORATE SOURCE: SF-02150, Finland

Tetrahedron (1987), '43(24), 6001-6 SOURCE:

CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal LANGUAGE: English

A new route using very mild reaction conditions, i.e. heating in EtOH, is described for the transformation of indoloquinolizidines I (R = Me, Et)

the 1-oxo-1,2,3,4-tetrahydro- β -carbolines II.

RX(2) OF 41 ...F + G ===> H...

L2 ANSWER 20 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

YIELD 98%

RX (2) RCT F 24424-99-5, G 13427-00-4 RGT I 32503-27-8 Bu4N.HS04 PRO H 116171-57-4 SOL 108-88-3 PhMe

RX(10) OF 41 COMPOSED OF RX(2), RX(3) f + G ===> K RX(10)

STEPS

L2 ANSWER 20 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

t-BuO O Me

K YIELD 91%

RX(2) RCT F 24424-99-5, G 13427-00-4 RGT I 32503-27-8 Bu4N.HSO4 PRO H 116171-57-4

SOL 108-88-3 PhMe

RX(3) RCT H 116171-57-4 RGT L 7722-84-1 H202 PRO K 116171-60-9 SOL 67-66-3 CHC13, 67-56-1 MeOH

RX(14) OF 41 COMPOSED OF RX(5), RX(2) RX(14) T + F ===> H

2 STEPS

L2 ANSWER 20 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

RX(2) RCT F 24424-99-5, G 13427-00-4 RGT I 32503-27-8 Bu4N.HSO4 PRO H 116171-57-4 SOL 108-88-3 PhMe

RX(3) RCT H 116171-57-4 RGT L 7722-84-1 H202 PRO K 116171-60-9 SOL 67-66-3 CHC13, 67-56-1 MeOH

RX(7) RCT K 116171-60-9

STAGE(1)

RGT R 407-25-0 (CF3C0) 20

SOL 75-09-2 CH2C12

STAGE(2)

NTE 73% overall

RGT AB 151-50-8 KCN SOL 7732-18-5 Water PRO W 116171-59-5, X 116171-59-6

RX(19) OF 41 COMPOSED OF RX(5), RX(2), RX(3), RX(7) RX(19) 2 T + 2 F ===> W + X

L2 ANSWER 20 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

H YIELD 98%

RX(5) RCT T 24716-23-2 RGT U 1333-74-0 H2 PRO G 13427-00-4 CAT 1314-15-4 PtO2 SOL 67-56-1 MeOH

RX(2) RCT F 24424-99-5, G 13427-00-4 RGT I 32503-27-8 Bu4N.HSO4 PRO H 116171-57-4 SOL 108-88-3 PhMe

RX(18) OF 41 COMPOSED OF RX(2), RX(3), RX(7) RX(18) 2 F + 2 G ==> W + X

3 STEPS

L2 ANSWER 20 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

t-BuO O NC H H H

RX(5) RCT T 24716-23-2

ANSWER 20 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) RGT U 1333-74-0 H2 PRO G 13427-00-4 CAT 1314-15-4 Pt02 SOL 67-56-1 MeOH RCT F 24424-99-5, G 13427-00-4 RX(2) RGT I 32503-27-8 Bu4N.HS04 PRO H 116171-57-4 SOL 108-88-3 PhMe RX (3) RCT H 116171-57-4 RGT L 7722-84-1 H202 PRO K 116171-60-9 SOL 67-66-3 CHCl3, 67-56-1 MeOH RCT K 116171-60-9 RX (7) STAGE(1) RGT R 407-25-0 (CF3CO) 20 SOL 75-09-2 CH2C12 STAGE (2) RGT AB 151-50-8 KCN SOL 7732-18-5 Water PRO W 116171-58-5, X 116171-59-6 NTE 73% overall RX(22) OF 41 COMPOSED OF RX(5), RX(2), RX(3)RX(22) T + F ===> K

ANSWER 20 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

YIELD 91%

RCT T 24716-23-2 RX(5) RGT U 1333-74-0 H2 PRO G 13427-00-4 CAT 1314-15-4 PtO2 SOL 67-56-1 MeOH RX (2) RCT F 24424-99-5, G 13427-00-4 RGT I 32503-27-8 Bu4N.HS04 PRO H 116171-57-4 SOL 108-88-3 PhMe RCT H 116171-57-4 RX(3)

RGT L 7722-84-1 H202 PRO K 116171-60-9

SOL 67-66-3 CHC13, 67-56-1 MeOH

L2 ANSWER 21 OF 31 CASREACT COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 109:37706 CASREACT TITLE: phthalyltryptamines

Indole derivatives. 129. Synthesis of disubstituted tryptamines by nitration of 5-methoxy-N-

Petrunin, I. A.; Vinograd, L. H.; Przhiyalgovskaya, AUTHOR (S): N.

F

M.; Suvorov, N. N. Mosk. Khim.-Tekhnol. Inst., Moscow, USSR CORPORATE SOURCE: SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1987), (8),

1050-3 CODEN: KGSSAQ; ISSN: 0453-8234 DOCUMENT TYPE: Journal

LANGUAGE: Russian

CH2CH2R

AB Nitration of 5-methoxy-N-phthalyltryptamine I (R = phthalimido, RI = H) with HNO3 in AcOH gives mainly I (R1 = NO2). I (R1 = NH2, NHAc) were obtained from I (R1 = NO2).

RX(2) OF 19 ...4 C ===> D + E + F + G...

С

L2 ANSWER 21 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) С

L2 ANSWER 21 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

D YIELD 42%

E YIELD 5%

L2 ANSWER 21 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

G YIELD 6%

RX(3) OF 19 ...2 C + 2 J ===> E + K

L2 ANSWER 21 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

(3)

E YIELD 9%

K YIELD 26%

RX(6) OF 19 ...2 D + 2 J ===> T + U

L2 ANSWER 21 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

$$\begin{array}{c} H \\ h \\ N \\ NO_2 \\ \end{array}$$

$$\begin{array}{c} Ac \\ Ac \\ \end{array}$$

$$\begin{array}{c} Ac \\ \end{array}$$

$$\begin{array}{c} Ac \\ \end{array}$$

T YIELD 12%

U . YIELD 34%

ANSWER 21 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) PRO T 115168-42-8, U 115168-41-7

RX(13) OF 19 COMPOSED OF RX(2), RX(6) 8X(13) 5 C + 2 J ===> T + U

¢

С

L2 ANSWER 21 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) RGT Q 1333-74-0 H2 CAT 7440-02-0 Ni SOL 68-12-2 DMF

> STAGE (2) RCT J 108-24-7

PRO T 115168-42-8, U 115168-41-7

L2 ANSWER 21 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

T YIELD 12%

YIELD 34%

RX (2) RCT C 55747-66-5

PRO D 115168-34-8, E 115168-35-9, F 115168-36-0, G 115168-37-1

SOL 64-19-7 ACOH

RCT D 115168-34-8 RX (6)

STAGE (1)

L2 ANSWER 22 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 108:204859 CASREACT

Novel applications of the modified Polonovski TITLE:

reaction. IX. New route to Wenkert's enamine Lounasmaa, Mauri; Karvinen, Esko; Koskinen, Ari; AUTHOR (S):

Jokela, Reija

Lab. Org. Bioorg. Chem., Tech. Univ. Helsinki, Espoo, CORPORATE SOURCE: SF-02150, Finland

Tetrahedron (1987), 43(9), 2135-46 SOURCE:

CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal English

LANGUAGE: GI

AB A practical synthetic entry to Wenkert's enamine (I) employing the modified Polonovski reaction is described. Complete 13C NMR spectral

of I is presented. Conformational anal. of the intermediate 1-hydroxyand 1-ethyl-1-hydroxyinodolquinolizidines II (R=H, Et) based on simple but reliable 13C NMR spectral correlations is presented.

RX(4) OF 62 ...I + L ===> M...

L2 ANSWER 22 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

t-Buo o Ph

M YIELD 90%

RX(4) RCT I 76509-19-8, L 24424-99-5 RGT N 1122-58-3 4-DMAP PRO M 114495-25-9 SOL 75-09-2 CH2C12

RX(14) OF 62 COMPOSED OF RX(3), RX(4) RX(14) G + L ===> M

L2 ANSWER 22 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

STEPS

H

Ph

MYIELD 90%

RX(3) RCT G 76509+18-7 RGT J 16940-66-2 NaBH4 PRO I 76509-19-8 SOL 64-17-5 EtOH

RX(4) RCT I 76509-19-8, L 24424-99-5 RGT N 1122-58-3 4-DMAP PRO M 114495-25-9 SOL 75-09-2 CH2C12

RX(15) OF 62 COMPOSED OF RX(4), RX(5) RX(15) I + L ==> P

2 STEPS

L2 ANSWER 22 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

t-BuO O CN Ph

P YIELD 100%

RX(4) RCT I 76509-19-8, L 24424-99-5 RGT N 1122-58-3 4-DMAP PRO M 114495-25-9 SOL 75-09-2 CH2C12

RX(5) RCT M 114495-25-9

STAGE(1) RGT Q 937-14-4 MCPBA SOL 75-09-2 CH2C12

RGT R 407-25-0 (CF3CO)20

STAGE(3) RGT S 151-50-8 KCN SOL 7732-18-5 Water

PRO P 114495-24-8

RX(25) OF 62 COMPOSED OF RX(3), RX(4), RX(5) RX(25) G + L = P

L2 ANSWER 22 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

STEPS

NC

Ph

YIELD 100%

RX(3) RCT G 76509-18-7 RGT J 16940-66-2 NaBH4 PRO I 76509-19-8 SOL 64-17-5 EtOH

RX(4) RCT I 76509-19-8, L 24424-99-5 RGT N 1122-58-3 4-DMAP PRO M 114495-25-9 SOL 75-09-2 CH2C12

RX(5) RCT M 114495-25-9

STAGE (1) RGT Q 937-14-4 MCPBA SOL 75-09-2 CH2C12

STAGE(2) RGT R 407-25-0 (CF3CO)20

STAGE(3) RGT S 151-50-8 KCN SOL 7732-18-5 Water

PRO P 114495-24-8

L2 ANSWER 23 OF 31 CASREACT COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 108:56422 CASREACT

TITLE:

Nitrogen assisted acetal ring cleavage. Part III. Synthesis and reactions of 1-formyl-3,4,6,7,12,12b-

hexahydroindolo[2,3-a]quinolizine

AUTHOR (S): Tolvanen, Arto; Lounasmaa, Mauri Lab. Org. Bioorg. Chem., Tech. Univ. Helsinki, Espoo, CORPORATE SOURCE:

SF-02150, Finland SOURCE:

Tetrahedron (1987), 43(6), 1123-7 CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal LANGUAGE: English

GI

III

AB N-Protection followed by oxidation and cyclization of indole I gave indoloquinolizine II. II was converted to indoloquinolizineacrylate III, which can be used as intermediate for the synthesis of eburnamine-vincamine alkaloids.

RX(3) OF 68

$$\begin{array}{c} & & & & & \\ & & & & \\ & & & & \\ & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

ANSWER 23 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

STEPS

H YIELD 95%

RX (2) RCT C 105702-50-9 RGT E 16940-66-2 NaBH4 PRO D 105688-95-7

SOL 64-17-5 EtOH

RX (3) RCT D 105688-95-7, G 1538-75-6 PRO H 112396-78-8 CAT 1122-58-3 4-DMAP SOL 75-09-2 CH2C12

RX(17) OF 68 COMPOSED OF RX(3), RX(4) RX(17) D + G $\Rightarrow\Rightarrow>$ K

L2 ANSWER 23 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

YIELD 95%

RCT D 105688-95-7, G 1538-75-6 PRO H 112396-78-8 RX (3) CAT 1122-58-3 4-DMAP SOL 75-09-2 CH2C12

RX(16) OF 68 COMPOSED OF RX(2), RX(3) RX(16) C + G ===> H

ANSWER 23 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

STEPS

K YIELD 91%

RCT D 105688-95-7, G 1538-75-6 RX (3) PRO H 112396-78-8 CAT 1122-58-3 4-DMAP

SOL 75-09-2 CH2C12

RCT H 112396-78-8 RX (4) RGT L 7722-84-1 H202 PRO K 112396-79-9 SOL 7732-18-5 Water, 64-17-5 EtoH, 67-66-3 CHC13

RX(28) OF 68 COMPOSED OF RX(2), RX(3), RX(4) RX(28) C + G ===> K

L2 ANSWER 23 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

> K YIELD 91%

RX(2) RCT C 105702-50-9 RGT E 16940-66-2 NaBH4 PRO D 105688-95-7 SOL 64-17-5 EtOH

RX(3) RCT D 105688-95-7, G 1538-75-6 PRO H 112396-78-8 CAT 1122-58-3 4-DMAP SOL 75-09-2 CH2C12

RX(4) RCT H 112396-78-8 RGT L 7722-84-1 H202 PRO K 112396-79-9 SOL 7732-18-5 Water, 64-17-5 EtOH, 67-66-3 CHCl3

RX(30) OF 68 COMPOSED OF RX(3), RX(4), RX(5) RX(30) D + G ===> O

L2 ANSWER 23 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) SOL 75-09-2 CH2Cl2

RX(31) OF 68 COMPOSED OF RX(2), RX(3), RX(4), RX(5) RX(31) C + G ==> 0

STEPS

O: CM 2

RX(2) RCT C 105702-50-9 RGT E 16940-66-2 NaBH4 PRO D 105688-95-7 SOL 64-17-5 EtOH

RX(3) RCT D 105688-95-7, G 1538-75-6 PRO H 112396-78-8 CAT 1122-58-3 4-DMAP SOL 75-09-2 CH2C12 L2 ANSWER 23 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

3
STEPS
F-C-CO2F
0: CM 1

0: CM 2

RX(3) RCT D 105688-95-7, G 1538-75-6 PRO H 112396-78-8 CAT 1122-58-3 4-DMAP SOL 75-09-2 CH2C12

RX(4) RCT H 112396-78-8 RGT L 7722-84-1 H202 PRO K 112396-79-9 SOL 7732-18-5 Water, 64-17-5 Etoh, 67-66-3 CHCl3

RX(5) RCT K 112396+79+9 RGT P 407-25-0 (CF3CO)20 PRO O 112418-33+4

L2 ANSWER 23 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) RX(4) RCT H 112396-78-8

RCT H 112396-78-8 RGT L 7722-84-1 H202 PRO K 112396-79-9

SOL 7732-18-5 Water, 64-17-5 EtOH, 67-66-3 CHC13

RX(5) RCT K 112396-79-9 RGT P 407-25-0 (CF3CO)20 PRO 0 112418-33-4 SOL 75-09-2 CH2C12 L2 ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 105:191462 CASREACT

TITLE: Synthesis of optically active isoquinuclidines utilizing a diastereoselectivity control element AUTHOR(S): Trost, Barry M.; Romero, Arthur G.

AUTHOR(S): Trost, Barry M.; Romero, Arthur G.
CORPORATE SOURCE: McElvain Lab. Org. Chem., Univ. Wisconsin-Madison,
Madison, WI, 53706, USA

SOURCE: Journal of Organic Chemistry (1986), 51(12), 2332-42

CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal

DOCUMENT TYPE: Journal LANGUAGE: English

GI

CH2 II

The development of a palladium-mediated cyclization via isomerization using a vinyl epoxide as an initiator and an amine as a terminator led to a facile cyclization to produce isoquinuclidines. The synthesis of the requisite cyclizaton precursor I from (-)-quinic acid led to the isoquinuclidine II in optically pure form. The substitution pattern of the resultant isoquinuclidine would allow further cyclization to either enantiomeric series of the iboga alkaloids. This "pseudo-meso" intermediate then can become a common intermediate to either ibogamine or catharanthine, the latter of particular importance in the synthesis of vinblastine analogs. The olefination of an epoxy ketone proceeds with high geometrical control.

RX(4) OF 305 ...L + M ===> N...

L2 ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

MeO O O N Bu-t Me Me Me

М

RX(4) RCT L 79-22-1, M 101917-36-6 RGT O 7693-26-7 KH PRO N 101917-37-7 SOL 109-99-9 THF

RX(38) OF 305 COMPOSED OF RX(4), RX(5) RX(38) L + M ===> Q

L2 ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

Cl CH3

CH3

Me3Si

Me Me Me

Me Me

2 STEPS

Q

MeO O H

RX(4) RCT L 79-22-1, M 101917-36-6

RGT O 7693-26-7 KH PRO N 101917-37-7 SOL 109-99-9 THF

RX(5) RCT N 101917-37-7 RGT R 64-19-7 AcOH

PRO Q 101917-38-8 SOL 7732-18-5 Water, 109-99-9 THF

RX(72) OF 305 COMPOSED OF RX(4), RX(5), RX(6) RX(72) L + M \Rightarrow T

L2 ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

C1 O CH3

L Me3Si O O Me Me Me

3 STEPS

T

М

RX(4) RCT L 79-22-1, M 101917-36-6

RGT O 7693-26-7 KH PRO N 101917-37-7 SOL 109-99-9 THF

RX(5) RCT N 101917-37-7 RGT R 64-19-7 Acoh

PRO Q 101917-38-8 SOL 7732-18-5 Water, 109-99-9 THF

RX(6) RCT Q 101917-38-8 RGT U 937-14-4 MCPBA PRO T 101932-70-1 SOL 75-09-2 CH2C12

RX(75) OF 305 COMPOSED OF RX(4), RX(5), RX(6), RX(7) RX(75) $L + M \approx > W$

```
L2 ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                            (Continued)
         . СНЗ
STEPS
         RCT L 79-22-1, M 101917-36-6
RX (4)
         RGT 0 7693-26-7 KH
         PRO N 101917-37-7
         SOL 109-99-9 THF
RX(5)
         RCT N 101917-37-7
         RGT R 64-19-7 AcOH
         PRO Q 101917-38-8
         SOL 7732-18-5 Water, 109-99-9 THF
RX(6)
         RCT Q 101917-38-8
         RGT U 937-14-4 MCPBA
         PRO T 101932-70-1
         SOL 75-09-2 CH2C12
```

```
ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                            (Continued)
         PRO T 101932-70-1
         SOL 75-09-2 CH2C12
RX (7)
         RCT T 101932-70-1
         RGT X 79-37-8 (COC1)2
         PRO W 101917-41-3
         SOL 75-09-2 CH2C12
RX (10)
         RCT AE 2065-66-9, W 101917-41-3
         RGT AF 865-47-4 t-BuOK
         PRO Y 101917-39-9
         SOL 109-99-9 THF
RX(132) OF 305 COMPOSED OF RX(4), RX(5), RX(6), RX(7), RX(34)
RX\{132\} L + M + CG ===> AI
                                                    • Br
М
                                                 CG
```

STEPS

```
02/21/2007
L2 ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                           (Continued)
         RCT T 101932-70-1
RX (7)
         RGT X 79-37-8 (COC1)2
         PRO W 101917-41-3
         SOL 75-09-2 CH2C12
RX(131) OF 305 COMPOSED OF RX(4), RX(5), RX(6), RX(7), RX(10)
RX(131) L + M + AE ==> Y
                          MeO.
 • I-
            STEPS
ΑE
                      Y
RX (4)
         RCT L 79-22-1, M 101917-36-6
         RGT O 7693-26-7 KH
         PRO N 101917-37-7
         SOL 109-99-9 THF
RX (5)
         RCT N 101917-37-7
         RGT R 64-19-7 ACOH
         PRO Q 101917-38-8
         SOL 7732-18-5 Water, 109-99-9 THF
RX (6)
         RCT Q 101917-38-8
         RGT U 937-14-4 MCPBA
L2 ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
                                                           (Continued)
ΑI
         RCT L 79-22-1, M 101917-36-6
RX (4)
         RGT 0 7693-26-7 KH
         PRO N 101917-37-7
         SOL 109-99-9 THF
RX (5)
         RCT N 101917-37-7
         RGT R 64-19-7 ACOH
         PRO Q 101917-38-8
         SOL 7732-18-5 Water, 109-99-9 THF
         RCT Q 101917-38-8
RX (6)
         RGT U 937-14-4 MCPBA
         PRO T 101932-70-1
```

L2 ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

```
CG
М
```

ΑK

RCT L 79-22-1, M 101917-36-6 RX (4)

RGT O 7693-26-7 KH PRO N 101917-37-7 SOL 109-99-9 THF

RX (5) RCT N 101917-37-7 RGT R 64-19-7 ACOH PRO Q 101917-38-8

SOL 7732-18-5 Water, 109-99-9 THF

RX(6) RCT Q 101917-38-8 RGT U 937-14-4 MCPBA PRO T 101932-70-1 SOL 75-09-2 CH2C12

L2 ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

ΑĢ

RX (4) RCT L 79-22-1, M 101917-36-6

RGT 0 7693-26-7 KH PRO N 101917-37-7 SOL 109-99-9 THF

RX (5) RCT N 101917-37-7 RGT R 64-19-7 ACOH

PRO Q 101917-38-8 SOL 7732-18-5 Water, 109-99-9 THF

RX(6) RCT Q 101917-38-8 RGT U 937-14-4 MCPBA PRO T 101932-70-1 SOL 75-09-2 CH2C12

RX (7) RCT T 101932-70-1 RGT X 79-37-8 (COC1)2 PRO W 101917-41-3 SOL 75-09-2 CH2C12

RX(10) RCT AE 2065-66-9, W 101917-41-3 RGT AF 865-47-4 t-BuOK PRO Y 101917-39-9 SOL 109-99-9 THF

RX(8) RCT Y 101917-39-9 RGT AA 429-41-4 Bu4N.F PRO Z 101917-42-4 SOL 75-05-8 MeCN

RX(11) RCT Z 101917-42-4 PRO AG 101917-43-5 CAT 14221-01-3 Pd(PPh3)4 SOL 109-99-9 THF

L2 ANSWER 24 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

RX (7) RCT T 101932-70-1 RGT X 79-37-8 (COC1)2 PRO W 101917-41-3 SOL 75-09-2 CH2C12

RX (34) RCT W 101917-41-3, CG 1530-32-1 RGT AF 865-47-4 t-BuOK PRO AI 101917-44-6 SOL 109-99-9 THF

RX(13) RCT AI 101917-44-6 PRO AK 101917-45-7 CAT 14221-01-3 Pd (PPh3) 4 SOL 109-99-9 THF

RX(156) OF 305 COMPOSED OF RX(4), RX(5), RX(6), RX(7), RX(10), RX(8), RX(11) RX(156) L + M + AE ===> AG

SiMe₃ ÆΕ

7 STEPS

L2 ANSWER 25 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 104:224804 CASREACT

TITLE:

Cobalt-mediated [2 + 2 + 2] cycloadditions of alkynes to the indole 2,3-double bond: an extremely facile entry into the novel 4a, 9a-dihydro-9H-carbazole

nucleus

Grotjahn, Douglas B.; Vollhardt, K. Peter C. Dep. Chem., Univ. California, Berkeley, CA, 94720, AUTHOR (S): CORPORATE SOURCE:

USA Journal of the American Chemical Society (1986), SOURCE:

108(8), 2091-3 CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

English LANGUAGE: GI For diagram(s), see printed CA Issue.

 η -Cyclopentadienyl cobalt (CpCo) reagent mediates the [2+2+2]cycloaddn. of the indole Me, etc., Z = O, H2; R1 = H, (CH2) 4C.tplbond.CH) complexed fused polyheterocycles with stereo- and regiospecificity. Thus, treating indoles I (n=2,3; R=H Me; Z=0 or

H2) with (Me3SiC.tplbond.)2 in the presence CpCo reagent cycloadducts II, along with cyclobutadiene compds. III.

RX(6) OF 42

RCT L 15741-71-6, B 55103-44-3 PRO M 101079-43-0

L2 ANSWER 25 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

RX(8) OF 42 P + B ===> Q...

$$C \equiv CH$$
 $C \equiv CH$
 $C \equiv CH$

RX(8) RCT P 62002-15-7, B 55183-44-3 PRO Q 101079-45-2

L2 ANSWER 26 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 104:129755 CASREACT TITLE: Carbon-13 NMR spectra

Carbon-13 NMR spectral and stereochemical analysis of piperidine-derived α-amino nitriles

Jokela, Reija; Tamminen, Tarja; Lounasmaa, Mauri Dep. Chem., Tech. Univ. Helsinki, Espoo, SF-02150/15, Finland

SOURCE: Heterocycles (1985), 23(7), 1707-22 CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal LANGUAGE: English

AUTHOR (S):

CORPORATE SOURCE:

Cyanopiperidines I and II [R = Et, CH2CH2CO2Me, CH2CH(CO2Me)2, 2-dioxolanyl, Rl = H; R = CH2CH(CO2Me)2, Rl = Et] were prepared by Palonovski cyanation of the piperidines III; the cyanotetrahydropyridines IV [R = Et, CH2CH2CO2Me, CH2CH(CO2Me)2] were obtained by reductive cyanation of the corresponding N-methylpyridinium iodides. C-13 NMR spectra were determined for I, II, and IV, substituent effects for the

group in the different N heterocycles were determined, and conformation-NMR

spectra correlations were made.

RX(36) OF 128 BR + BS ===> BT...

L2 ANSWER 26 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

вт

Q

RX(36) RCT BR 2671-39-8, BS 24424-99-5 RGT BU 1310-73-2 NaOH, BV 32503-27-8 Bu4N.HSO4 PRO BT 101026-08-8 SOL 7732-18-5 Water, 108-88-3 PhMe

RX(69) OF 128 COMPOSED OF RX(36), RX(37) RX(69) BR + BS ===> BW

L2 ANSWER 26 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

BW

RX(36) RCT BR-2671-39-8, BS 24424-99-5

RGT BU 1310-73-2 NaOH, BV 32503-27-8 Bu4N.HSO4 PRO BT 101026-08-8

SOL 7732-18-5 Water, 108-88+3 PhMe

RX(37) RCT BT 101026-08-8 RGT AY 7722-84-1 H202

PRO BW 101026-09-9 SOL 67-66-3 CHC13, 67-56-1 MeOH

RX(106) OF 128 COMPOSED OF RX(36), RX(37), RX(38) RX(106) 2 BR + 2 BS ===> BY + BZ

3 STEPS L2 ANSWER 26 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

t-BuO t-BuO BY

ΒZ

RCT BR 2671-39-8, BS 24424-99-5 RX (36)

RGT BU 1310-73-2 NaOH, BV 32503-27-8 Bu4N.HSO4 PRO BT 101026-08-8

SOL 7732-18-5 Water, 108-88-3 PhMe

RCT BT 101026-08-8 RX(37) RGT AY 7722-84-1 H202

PRO BW 101026-09-9 SOL 67-66-3 CHC13, 67-56-1 MeOH

RCT BW 101026-09-9 RX (38)

STAGE (2)

STAGE (1) RGT BC 407-25-0 (CF3CO) 20

SOL 75-09-2 CH2C12

RGT BD 151-50-8 KCN, BE 127-09-3 AcONa . SOL 7732-18-5 Water, 75-09-2 CH2Cl2

PRO BY 101026-10-2, BZ 101026-11-3

L2 ANSWER 27 OF 31 CASREACT COPYRIGHT 2007 ACS on STN 103:160750 CASREACT

ACCESSION NUMBER: TITLE: Novel applications of the modified Polonovski

reaction

- VIII. Synthetic studies in the pseudovincamine

Jokela, Reija; Schuller, Siv; Lounasmaa, Mauri AUTHOR (S): CORPORATE SOURCE: Dep. Chem., Tech. Univ. Helsinki, Espoo, SF-02150/15,

Finland Heterocycles (1985), 23(7), 1751-7 SOURCE:

CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal LANGUAGE: English

CO2CMe3 MeO2C

Indoloquinolizine I, a potential intermediate in the pseudovincamine series, was synthesized via Polonovski reaction of piperidinoethylindole II (R = R1 = H) to give II (R = H, R1 = cyano, R = cyano, R1 = H). The conformations of I were discussed.

RX(5) OF 36

L2 ANSWER 27 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

RX (5) RCT K 98664-66-5, M 24424-99-5

N

STAGE (1) RGT 0 1310-73-2 NaOH CAT 32503-27-8 Bu4N.HSO4

SOL 108-88-3 PhMe, 7440-37-1 Ar

STAGE (2)

SOL 108-88-3 PhMe

RX(12) OF 36 COMPOSED OF RX(4), RX(5) RX (12)

J + M ===> N

PRO N 98677-51-1

M

L2 ANSWER 27 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

t-BuO 2 STEPS

RX (4) RCT J 98664-65-4 RGT L 1333-74-0 H2 PRO K 98664-66-5

RX(5) RCT K 98664-66-5, M 24424-99-5

STAGE(1) RGT O 1310-73-2 NaOH CAT 32503-27-8 Bu4N. HSO4 SOL 108-88-3 PhMe, 7440-37-1 Ar STAGE (2) SOL 108-88-3 PhMe

RX(13) OF 36 COMPOSED OF RX(5), RX(6) RX(13) K + M ===> S

PRO N 98677-51-1

L2 ANSWER 27 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

2
STEPS

N
OMe

RX(5) RCT K 98664-66-5, M 24424-99-5

STAGE(1) RGT O 1310-73-2 NaOH CAT 32503-27-8 Bu4N.HSO4 SOL 108-88-3 PhMe, 7440-37-1 Ar

STAGE(2) SOL 108-88-3 PhMe

PRO N 98677-51-1

RX(6) RCT N 98677-51-1 RGT T 7722-84-1 H202 PRO S 98664-67-6 SOL 67-66-3 CHCl3, 67-56-1 MeOH

RX(21) OF 36 COMPOSED OF RX(4), RX(5), RX(6) RX(21) J + M ===> S

L2 ANSWER 27 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

● Br - t-BuO OBu-t

STEPS

W

H

H

OME

RX(4) RCT J 98664-65-4 RGT L 1333-74-0 H2 PRO K 98664-66-5

RX(5) RCT K 98664-66-5, M 24424-99-5

SOL 108-88-3 PhMe

STAGE(1)

RGT O 1310-73-2 NaOH

CAT 32503-27-8 Bu4N.HSO4

SOL 108-88-3 PhMe, 7440-37-1 Ar

STAGE(2)

L2 ANSWER 27 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued) PRO N 98677-51-1

RX(6) RCT N 98677-51-1 RGT T 7722-84-1 H2O2 PRO S 98664-67-6

RX(23) OF 36 COMPOSED OF RX(5), RX(6), RX(8) RX(23) 2 K + 2 M ===> W + AB

SOL 67-66-3 CHC13, 67-56-1 MeOH

OMe

t-BuO

OBu-t

2 K

3 STEPS

t-BuO O CN O OMe

L2 ANSWER 27 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

t-BuO O CN CN Et

AB

RX(5) RCT K 98664-66-5, M 24424-99-5

STAGE(1)

RGT O 1310-73-2 NaOH

CAT 32503-27-8 Bu4N.HSO4

SOL 108-88-3 PhMe, 7440-37-1 Ar

STAGE (2) SOL 108-88-3 PhMe

PRO N 98677-51-1

RX(6) RCT N 98677-51-1 RGT T 7722-84-1 H2O2 PRO S 98664-67-6 SOL 67-66-3 CHCl3, 67-56-1 MeOH

RX(8) RCT S 98664-67-6

STAGE(1) RGT AC 407-25-0 (CF3CO)20 SOL 75-09-2 CH2C12, 7440-37-1 Ar

STAGE (2) RGT AD 151-50-8 KCN SOL 7732-18-5 Water

PRO W 98664-69-8, AB 98664-68-7

RX(24) OF 36 COMPOSED OF RX(4), RX(5), RX(6), RX(8) RX(24) $2 J + 2 M = \Rightarrow W + AB$

L2 ANSWER 27 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

L2 ANSWER 27 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

AB

RX(5) RCT K 98664-66-5, M 24424-99-5

STAGE(1)
RGT O 1310-73-2 NaOH
CAT 32503-27-8 Bu4N.HSO4
SOL 108-88-3 PhMe, 7440-37-1 Ar
STAGE(2)

SOL 108-88-3 PhMe PRO N 98677-51-1

RX(6) RCT N 98677-51-1 RGT T 7722-84-1 H2O2 PRO S 98664-67-6 SOL 67-66-3 CHC13, 67-56-1 MeOH

RX(8) RCT S 98664-67-6

STAGE(1)

RGT AC 407-25-0 (CF3CO)20

SOL 75-09-2 CH2C12, 7440-37-1 Ar

STAGE(2) RGT AD 151-50-8 KCN SOL 7732-18-5 Water

PRO W 98664-69-8, AB 98664-68-7

L2 ANSWER 27 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

L2 ANSWER 28 OF 31 CASREACT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 102:185337 CASREACT
TITLE: Studies of rutaecarpine and related quinazolinocarboline alkaloids

AUTHOR(S):

CORPORATE SOURCE:

Dep. Org. Chem., R. Inst. Technol., Stockholm, S-100
44, Swed.

SOURCE:

Journal of Organic Chemistry (1985), 50(8), 1246-55

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal LANGUAGE: English

Quniazolinocarboline alkaloids, e.g., rutaecaprine (I), can readily be synthesized by treating tryptamine with 2-(trifluoromethyl)-4H-3,1-benzoxazin-4-one which was generated in situ from (F3CCO)2O and 2H-3,1-benzoxazine-2,4(IH)-dione. The product formed, (indolylethyl) (trifluoromethyl) quinazolinone II, is then cyclized (HC1/HOAc) to (trifluoromethyl) dihydrorutaecarpine III (R = F3C), from which CF3H is eliminated by treatment with base. The sequence can conveniently be performed as a three-reaction one-pot procedure giving I in 99% yield within 3 h. The approach can readily be extended to the synthesis of evodiamine, 13,13b-dehydroevodiamine, and 13b,14-dihydrorutaecarpine (III, R = H). Thus treatment of 3-[2-(3-indolyl)ethyl]-4(3H)-quinazolinone with (F3CCO)2O gave (trifluoroacetyl)-13b,14-dihydrorutaecarpine, which was hydrolyzed to III

RX(11) OF 205 ...X ===> Z

AB

L2 ANSWER 28 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

RX(11) RCT X 60941-86-8 RGT AA 64-18-6 HCO2H PRO Z 95274-45-6 SOL 64-18-6 HCO2H

RX(12) OF 205

L2 ANSWER 28 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

RX (12) RCT X 60941-86-8, G 108-24-7 PRO AB 95274-46-7

SOL 108-24-7 Ac20

L2 ANSWER 29 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

97:6148 CASREACT ACCESSION NUMBER:

TITLE: Indole derivatives and their medicinal use Coates, I. H.; Dowle, M. D.; Mills, K.; Bays, D. E.; INVENTOR(S):

Webb, C. F. PATENT ASSIGNEE(S): Glaxo Group Ltd., UK

SOURCE: Belg., 82 pp.

DOCUMENT TYPE: LANGUAGE: Patent French

OTHER SOURCE(S):

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
BE 689931	A1	19820211		1981-205644	19810811
DK 8103572	A	19820213	DK	1981-3572	19810811
DK 157995	В	19900312			
DK 157995	¢	19900806			
SE 8104783	A	19820213	5Ē	1981-4783	19810811
SE 454777	В	19880530			
SE 454777	С	19880922			
AU 8173995	A	19820218	AU	1981-73995	19810811
AU 550010	B2	19860227	•		
FR 2488606	Al	19820219	FR	1981-15515	19810811
FR 2488606	B 1	19841026			•
NL 8103764	A	19820301		1981-3764	19810811
GB 2083463	A	19820324	GB	1981-24478	19810811
GB 2083463	В	19840510			
DE 3131752	A1	19820616	DE	1981-3131752	19810811
DE 3131752	Ç2	19920423			
ES 504694	A1	19821101		1981-504694	19810811
ZA 8105541	A	19830330		1981-5541	19810811
CH 652394	A5	19851115		1981-5161	19810811
JP 57059865	A	19820410	JP	1981-125413	19810812
JP 01048896	В	19891020			
CA 1165765	A1	19840417		1981-383680	19810812
ES 513934	Al	19840601		1982-513934	19820713
US 4672067	A	19870609		1984-625648	19840628
US 4636521	A	19870113		1984-626383	19840629
AT 8403184	A	19860315	AT	1984-3184	19841008
AT 381491	В	19861027			
US 4839377		19890613		1987-82132	19870806
RITY APPLN. IN	FQ.:			1980-26287	19800812
				1980-26288	19800812
•				1981-3528	19810811
				1981-291997	19810811
				1981-292022	19810811
				1981-292023	19810811
				1982-404872	19820803
				1982-431597	
				1983-461278	19830126
			US	1985-711152	19850313

MARPAT 97:6148

L2 ANSWER 29 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

AB I [R, R1, R2, R4, R6 = H, alkyl; R3 = H, alkyl, cycloalkyl, alkenyl, aralkyl; R5 = CHO, acyl, esterified CO2H, (un)substituted carbamoyl, thiocarbamoyl, sulfamoyl; n = 0, 1; Z = alkylene, mono- or dialkylalkylene; or NR2R3 form a heterocycle or R2R3 = aralkylidene] were prepared and they are useful as antihypertensives (no data, formulations

given). 5-(Aminomethyl)-3-(2-phthalimidoethyl)indole reacted with Ac2O, and the product was hydrazinolyzed to give 5-(acetamidomethyl)-3-(2aminoethyl) indole.

RX(7) OF 9

RX(7) RCT J 82017-03-6 PRO K 82017-04-7

ANSWER 29 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

ANSWER 30 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

94:47067 CASREACT ACCESSION NUMBER: TITLE:

Synthesis and reactions of N-protected 2-lithiated

pyrroles and indoles. The tert-butoxycarbonyl

substituent as a protecting group Hasan, Iltifat: Marinelli, Edmund R.; Lin, Li-Ching

Chang; Fowler, Frank W.; Levy, Alan B. CORPORATE SOURCE: Dep. Chem., State Univ. New York, Stony Brook, NY,

11794, USA SOURCE:

Journal of Organic Chemistry (1981), 46(1), 157-64

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal LANGUAGE: English

AUTHOR (5):

N-(tert-Butoxycarbonyl)pyrrole and N-tert-(butoxycarbonyl)indole were prepared and lithiated at C-2 with lithium 2, 2, 6, 6-tetramethylpiperidide

Me3CLi, resp. The lithium reagents react with a variety of electrophiles to give C-2 substituted N-(tert-butoxycarbonyl)pyrroles and N-(tert-butoxycarbonyl)indoles. The tert-butoxycarbonyl group may be removed rapidly and in high yield from the pyrrole derivs. under basic conditions. For the indole derivs., the protecting group may be removed

RX(11) OF 14

either with acidic or basic conditions.

ANSWER 30 OF 31 CASREACT COPYRIGHT 2007 ACS on STN (Continued)

AB YIELD 97%

RCT AA 343227-24-7, M 1070-19-5 RX (11) PRO AB 75400-70-3

L2 ANSWER 31 OF 31 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 92:215199 CASREACT TITLE:

New method for the N-alkylation of indoles AUTHOR (S): Suvorov, N. N.; Plutitskii, D. N.; Smushkevich, Yu.

Mosk. Khim. Tekhnol. Inst., Moscow, 125047, USSR

CORPORATE SOURCE: SOURCE:

Khimiya Geterotsiklicheskikh Soedinenii (1980), (2),

CODEN: KGSSAQ; ISSN: 0453-8234

DOCUMENT TYPE: Journal LANGUAGE: Russian

GI

AB Treatment of indole I (R = H, Me, CH2CH2NMe2) with Bu4N+Br- in sulfolane containing K2CO3 at 170° for 3 h gave N-butylindoles II. Substitution in the 2 position of the indole ring prevented N-alkylation due to steric hindrance. 1-Butyl-N, N-dimethyltryptamine was prepared similarly.

Skatole was heated similarly to give N-butylskatol.

RX(3) OF 3